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Abstract 
Subsets of morbidly obese patients do not appear to exhibit the expected comorbidities, as 
well as the fact that heightened sympathetic nervous system (SNS) activity has been known to 
affect metabolism.  In this study, Neuropeptide Y (NPY), an SNS co-transmitter is explored as a 
possible  biomarker  for  unhealthy  obesity.    The  aims  of  the  study  were  to  identify  a  
normoinsulinemic/insulin  sensitive  morbidly  obese  Caucasian  patient  cohort,  compare 
differences in NPY levels in the circulation and adipose tissue between the normoinsulinemic 
and hyperinsulinemic subjects.    I explored the hypothesis that elevated circulating peripheral 
NPY causes metabolic abnormalities by mediating changes in the normal function of brain stem 
regulatory mechanisms via inflammation of astrocytes as shown in an in vitro model of primary 
cell line of human fetal brain stem astrocyte cell line. 
Blood and abdominal adipose tissue samples were obtained from consenting, morbidly 
obese patients awaiting bariatric surgery for recruitment in the study. Adipokines and NPY were 
measured as well as gene and protein expression by real-time PCR and histology. Effect of NPY 
was  determined  on  a  human  brainstem  astrocytic  primary  cell-line  using 
immunohistochemistry, real time PCR, cytokine ELISA, intracellular secondary messengers via 
ELISA and fluorescence microscopy. Secreted lactate levels were measured by calorimetric 
assays. Differences were found between metabolically healthy obese (MHO) and pathologically 
obese (PO)/diabetic groups in certain adipokines and insulin sensitivity, which were maintained 
after surgical weight loss. Differences in adipocyte cell size were visible between the two groups 
both in subcutaneous and omental adipose tissue depots but inflammatory cell infiltration was 
not  different.  Brain  stem  astrocytes  expressed  NPY  receptors  and  IL-6  secretion  from  the 
astrocytes increased when exposed to a combination of NPY and noradrenaline, reflected by 
changes  in  intracellular  cAMP.  Cytokine  array  showed  increases  in  various  inflammatory 
cytokines under the same treatment. IL-6 treatment increased astrocyte lactate levels. 3 
 
In astrocytes there was greater level of adrenergic signalling and secretion of IL-6 and lactate 
by the cells, which could mean different metabolic balance of astrocytes and long-term effects 
on astrocyte chemosensing function. These findings suggest differences in susceptibility to 
obesity associated pathologies linked to a synergistic modulation between the intracellular 
signalling pathways of astrocytes, being regulated at least partially by components of the CNS 
and having a direct effect on the cells. Perhaps these would pave the way for targeted treatment 
modalities. In vivo studies in an analogous animal model would further clarify the connection 
between  elevated  peripheral  NPY  and  its  central  effects  on  the  brainstem  astrocytes  in 
mediating metabolic disease. 
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1.1 The obesity epidemic and its impact on society 
Obesity is defined as abnormal or excessive fat accumulation that may impair health (1). 
This excessive fat accumulation is accommodated by the expansion of existing adipose tissue 
depots of the organism and is mostly caused by an excessive caloric intake coupled with a 
sedentary lifestyle  (2). Obesity is associated with a variety of comorbidities and is currently a 
growing economic burden on the National Health Service in the United Kingdom, with a growing 
number of clinical resources being allocated to the treatment of the phenomenon every year.  
Direct costs of treating obesity and obesity related comorbidities incurred by the NHS have risen 
from £479.3 million in 1998 to £4.2 billion in 2007, and indirect costs have been estimated to 
range from £600 million to £1.4 billion in 2007 (3). Modelled projections regarding the current 
trend of indirect costs estimate them to rise to £27 billion in 2015 (3). 
 
 
 
Figure 1: Number of hospital episodes for bariatric surgery in England by sex 2003/4-
2009/10 (Source: (4)) 
 19 
 
As shown in Figure 1, hospital episodes for surgical interventions to facilitate weight loss, 
such as gastric bypass and gastric banding, have been steadily increasing every year. In the UK 
currently there are approximately 12.3 of such procedures per 100,000 population (4), reflecting 
the rising need for treatment for obesity and morbid obesity,. Added to this economic and social 
burden are the greater numbers of overweight individuals, which, in 2009 were estimated to 
account for 63% of males and 52% of females(5). In the face of the increasing prevalence of all 
forms of obesity, the need to tackle the disease and its co-morbidities, along with the costs 
associated with its treatment, are paramount. 
In  addition  to  the  monetary  considerations  of  preventing  the  spread  of  the  obesity 
epidemic, there is the important disabling effect that the condition can have on the population, 
calculated in 2002 as 7% of European total Disability Adjusted Life Years (DALY, a figure used to 
express the quantity of time spent with obesity-related comorbidities and the years of life lost 
due to the disability compared to the average European lifespan(6). These data make obesity a 
tripartite  issue,  comprising  of  human, economic  and  demographic  components,  worthy of 
greater investigation and a social understanding of the disease, rather than victimisation and 
stigmatisation of the sufferers(5)  
1.2 Obesity and comorbidities  
Obesity is associated with the increased risk of numerous metabolic complications, such as 
insulin  resistance,  dyslipidaemia,  hypertension,  and  various  cancers  (7–10).  While  insulin 
resistance and endothelial dysfunction are risk factors for all of these metabolic diseases the 
precise molecular mechanisms that may explain the associations between obesity and its co-
morbidities is, as yet, poorly understood. Effective prevention and novel therapies require 
elucidation of the mechanisms underlying these interactions, which will be described in the 
following sections. 
1.2.1 Cardiovascular disease and obesity 
One  of  the  most  common  comorbidities  associated  with  obesity  is  the  emergence  of 
cardiovascular disease, more commonly arising  in the forms of endothelial dysfunction in the 20 
 
intima media of the blood vessel wall, which can then lead to the formation of atherosclerotic 
plaques (11,12), or a hypertensive circulatory state. This is observed across various ethnicities 
as BMI increases in the population (13), with endothelial dysfunction being correlated with 
visceral  adiposity  in  various  obese  populations  (14).    The  mechanisms  linking  obesity  to 
endothelial dysfunction on the other hand are relatively poorly understood, despite evidence 
from various studies  suggesting that an obese state, which leads to increased reactive oxygen 
species, due to hyperglycaemia and the resulting sequestration of intracellular nitric oxide (15), 
reduces the vessel’s ability to dilate, which could then allow the dysfunction to develop into a 
full-fledged  hypertensive  state  if  left  unchecked  and  allowed  to  progress  as  obesity  is 
maintained.  
 
 
Figure 2: Mechanisms linking the obese state and hypertension (FFA = Free Fatty Acids, 
SNA = Sympathetic Nervous System Activity, RAS = Renin-Angiotensin System) 21 
 
Another contributing change which occurs in the obese state and known to contribute to 
the development of obesity associated hypertension (Figure 2) is the activity of the sympathetic 
nervous system (SNS). SNS activity is markedly increased in both human and animal models of 
dietary obesity (16). It is known to affect kidney sodium and water retention capability (17), 
mediated through the hypothalamic action of circulating leptin levels (15). Also, higher levels of 
systemic insulin, which often accompany obesity, affect SNS activity (15). 
1.2.2 Obstructive Sleep Apnoea (OSA) and obesity 
Another common comorbidity associated with a greater body mass is obstructive sleep 
apnoea (OSA), an episodic and repetitive interruption of the upper airways characterised by 
oxygen  desaturations  and  sleep  fragmentation  (18).  Despite  the  symptoms  of  OSA  being 
detected as daytime tiredness and snoring, the disease has been associated with a number of 
cardiovascular  complications  (19),  heightened  SNS  activity  (20)  and  even  abnormalities  in 
glucose homeostasis regulation (18,20). The mechanisms for these types of abnormalities still 
has to be elucidated, but SNS activity which is known to be heightened may account for the  
changes in blood pressure and breathing control observed in OSA patients (21). 
1.2.3 Non-Alcoholic Fatty Liver Disease (NAFLD) and obesity 
A high-energy dietary intake is also associated with the presence of greater amounts of 
saturated fatty acids (SFAs) which is metabolised by the liver. In a normal and fed state, the 
monosaccharides and amino acids that enter the circulation are taken up by hepatocytes and 
converted into fatty acid-CoA through an acetyl-CoA intermediate step. The first fatty acid 
products  are  in  the  saturated  form  and  polyunsaturated  fatty  acids  are  created  with 
modifications by desaturase enzymes (e.g. SCD1). Newly synthesized fatty acids are inserted into 
complex lipids, which in turn are packed into very low density lipoprotein (VLDL) particles and 
thus  secreted  (22).  Impairment  in  any  of  the  steps  of  this  pathway,  may  it  be  due  to 
oversaturation of lipid supply (23), either through the increase of intracellular reactive oxygen 
species  generated  by  mitochondrial  dysfunction  (24),  which  in  turn  cause  heightened 
intracellular inflammation signalling, or hyperinsulinemia triggered by greater levels of glucose 22 
 
in overfeeding (25), causes a build-up of fatty acids, with histologically visible cytosolic lipid 
vacuoles in hepatocytes. The way these lipid droplets are accumulated can vary with genetic 
variance in the expression and function of droplet trafficking-associated genes, some of which 
are currently under study as a factor for predisposition to NAFLD (such as Liver Triglyceride 
Hydrolase, TGH) and that could impair liver function in the face of heightened lipogenesis (26). 
 This build-up of intracellular lipids then causes fibrotic injuries which are similar to the 
resulting damage caused in alcoholic liver disease (25), with impaired liver function and cirrhosis 
at later stages if left untreated. The mechanisms underlying a predisposition to the disease in 
an obese population are yet not fully understood, and need further study in order to elucidate 
the molecular mechanisms involved in NAFLD and the possible metabolic differences that could 
underlie the incidence of the disease in obese populations worldwide. 
 
1.3 Obesity and insulin resistance 
 
Figure 3: Hyperinsulinemia in obesity (Source: (27)) 23 
 
The most important and significant comorbidity associated with obesity, mainly due to its 
effects on the onset of other disease characteristics is insulin resistance (IR). Insulin resistance 
may be defined as a progressive resistance of various insulin-responsive organs in the body to 
the effects of circulating insulin. The current understanding of the overall mechanisms that 
explain insulin resistance in obesity (Figure 3), suggests that the onset of IR is preceded by 
increased insulin secretion by the β-cells along with lower clearance of insulin by the liver and 
kidneys leading to systemic hyperinsulinemia. The development of the IR may be to compensate 
for  this  hyperinsulinemia  to  maintain  glucose  homeostasis  before  deteriorating  into  frank 
diabetes.  The cross-talk between insulin-responsive tissues is illustrated in Figure 4, where in 
response to glucose levels rising in the bloodstream insulin secretion is stimulated and causes 
uptake of glucose by the skeletal muscle and adipose tissue. High insulin levels also decrease 
free fatty acid (FFA) levels through inhibition of lipolysis by the adipose tissue, and decrease 
gluconeogenesis in the liver, as well as increasing leptin secretion by the adipose tissue. The 
resulting pathologies arising from the development of insulin resistance could alter the balance 
of this crosstalk, with a shift to rising FFA levels due to the lack of the lipolysis-inhibiting effect 
of insulin signalling on adipose tissue, as well as impaired control of gluconeogenesis and 
glucose  uptake,  which  could  ultimately  lead  to  Type  2  diabetes  mellitus  as  the  disease 
progresses and this balance is altered chronically (8,28,29).  
The correlation between obesity and insulin resistance has been investigated using various 
techniques (8,28), including oral glucose tolerance tests (OGTT) and the (8,28), the euglycaemic 
hyperinsulinaemic clamp, often described as the gold standard for measuring insulin sensitivity 
in  vivo.  Insulin  sensitivity  in  humans  effectively  decreases  by  30-40%  when  body  weight 
increases past ideal levels by >35-40% (28) and the development of insulin resistance has been 
directly shown to occur in response to experimental overfeeding in normal weight individuals 
(2). Progressive exacerbation of insulin resistance to type 2 diabetes following a prolonged state 
of hyperinsulinemia has also been reported (8,28,30). The symptomatic manifestation of insulin 
resistance involves the concerted action of all of the insulin-responsive tissues (as shown in 24 
 
Figure 4) in the body: skeletal muscle, the liver and adipose tissue, with varying effects at the 
systemic level: all of which will be briefly reviewed in the next section.  
 
 
Figure 4: Crosstalk of insulin-sensitive tissues in the body (Source: (31), FFA = Free Fatty 
Acids) 
 
1.3.1 Insulin resistance and skeletal muscle 
The skeletal muscle has been estimated to carry out approximately 80% of total body 
glucose uptake in response to insulin secretion (32). In obese normal glucose tolerant patients, 
there is marked insulin resistance in skeletal muscle compared to lean, age- and sex-matched 
individuals (32). Animal, as well as, human studies have shown a direct correlation between 
increase in body mass and skeletal muscle insulin resistance, suggesting that skeletal muscle 
dysfunction may be a the primary defect in the development of insulin resistance and type 2 
diabetes (32,33).  
The  reason  for  this  increased  insulin  resistance  in  skeletal  muscle  is  partially  due  to 
increased free fatty acid (FFA) levels in the circulation of obese and morbidly obese patients, as 25 
 
reported previously(32,34).  The reasons for the increased levels of free fatty acids in the 
circulation of obese patients was originally hypothesized by Randle et al. (35) to be due to the 
increased mass of the adipose tissue of obese individuals which in turn causes higher levels of 
circulating FFAs, which then interfere with glucose metabolism by overriding normal energy 
metabolism towards fatty acid oxidation instead of glycolysis, therefore causing build-up of 
glucose and worsening of insulin resistance (35,36). These fatty acids, which have been shown 
to increase insulin resistance after infusions in experimental models (32,33), are thought to act 
through the activation of inhibitory protein kinases such as JNK and Protein Kinase C which 
inhibit IRS-1 function in the insulin signalling pathway (32). 
1.3.2 Insulin resistance and the liver 
 
 
Figure 5: Insulin resistance in the liver. (Left: insulin sensitive liver. Right: Insulin 
resistant liver) (Source:(37)) 
 
Insulin resistance in the human liver is closely associated with raised intracellular fatty acid 
levels, which could allow the emergence of the previously discussed non-alcoholic fatty liver 26 
 
disease, or NAFLD. This coupled with evidence of elevated hepatic lipid levels in mice with 
specific deletions of vital insulin-responsive genes, such as the GLUT4 glucose transporter (37), 
has led to the suggestion that insulin resistance in obesity could be the main cause of NAFLD,  
through impaired signalling of the insulin receptor by protein kinase C activation (as shown in 
Figure 5) by free fatty acids (specifically diacylglycerols) associated with heightened caloric 
intake during obesity (37,38). This is in turn is exacerbated by the heightened levels of circulating 
glucose which are then thought to be converted into a greater amount of fatty acids by the liver 
through de novo lipogenesis, which in turn further increases insulin resistance in the organ itself 
(39). This is shown by studies illustrating the activation by insulin of SREBP-1c, a transcription 
factor responsible for the activation of lipogenesis genes (37,38). The activity of this gene will 
be discussed later in this introduction.  
Since the liver is considered a very important organ in IR, changing levels of liver enzymes 
involved in lipid metabolism which occur due to the modulation of intracellular signalling, 
specifically  in  enzymes  like  alanine  aminotransferase  (ALT)  are  being  proposed  as  part  of 
metabolic syndrome due to their readily detectable changes in a clinical setting, as well as direct  
analysis of the ratio of circulating fatty types as an indicator of fatty acid accumulation in the 
liver (40) for indication of liver insulin resistance and cardiometabolic syndrome onset in obesity 
and morbid obesity.   
1.4 Insulin resistance and the adipose tissue 
1.4.1 Adipose tissue: an endocrine organ 
Being  directly  involved  with  its  expansion  in the  onset and  exacerbation  of obesity  in 
response to overfeeding, and the main organ involved in long term energy storage, the adipose 
tissue  is seen as a central player in the onset of the various comorbidities associated with 
obesity itself (41). It is also recognized as being an important participant in the metabolism and 
homeostasis of glucose levels in the body (42), as well as an extremely diverse and important 
secretory organ, secreting a wide array of adipokines such as leptin, IL-6, adiponectin, MCP-1 
and TNF-α (See Figure 6). These are known to have effects at the local tissue and systemic levels 27 
 
(43). The biological activity and systemic effects of these adipokines have been extensively 
reviewed in various publications (41,43–45).   
 
Figure 6: Adipose tissue adipokines (Source:(44) ) 
 
The anatomical location of the adipose tissue and its expansion in different parts of the body 
can alter the secretory profile of these adipokines, with visceral depots having a more pro-
inflammatory secretory profile in humans (41), and are able to modulate the function of immune 
system cells such as T-cells at a local and systemic level (46).  The expansion of this depot 
specifically in the obese state is thought to promote greater metabolic risk in humans (43). 
Nevertheless, its central role as a secretory organ and metabolic hub of energy expenditure 
makes it a vital organ for the study of insulin resistance in obesity. 
1.4.2 Adipose tissue remodelling and insulin resistance in obesity: Hypertrophy vs. hyperplasia 
Adipose tissue undergoes expansion during excessive caloric intake, leading to its necessary 
remodelling. It has been hypothesized that impairments in the ability of the adipose tissue to 
generate new cells through differentiation of pre-adipocytes in the process of adipogenesis 
(hyperplasia) could be linked to the development of insulin resistance and diabetes mellitus (43), 
and that the enlargement of adipocytes associated with excess caloric intake (hypertrophy) is 28 
 
correlated with necrosis of the adipocytes themselves, a heightened local inflammatory state 
and the recruitment of monocytes of the immune system as a response (47,48).  
 
 
Figure 7: Adipose tissue hypertrophy and its local effects in obesity (Source: adapted 
from (43)) Note: black “dots” represent infiltrated monocytes in the adipose tissue 
 
The evidence showing that adipocyte inflammation signalling caused by the presence of 
macrophages in the adipose tissue is linked to insulin resistance (49) has led to a proposed 
model for the change of adipose tissue function as a response to over nutrition is illustrated in 
Figure 7, where in a lean, healthy state adipose tissue is insulin sensitive, with a secretory 
balance focused towards a less inflammatory profile. In the occurrence of over nutrition and 
forced  adipose  tissue  expansion,  the  hypertrophied  adipocyte  shifts  its  secretory  balance 
towards a more inflammatory profile, with less anti-inflammatory adipokines like adiponectin 
secreted  and  more  inflammatory  cytokines  such  as  interleukin-6  (IL-6)  and  Monocyte 
Chemotactic Protein 1 (MCP-1) being more readily secreted and present at a local level. This 29 
 
causes the recruitment of adipose tissue macrophages which in turn focus around necrotic 
adipocytes (48) and cause yet more heightened inflammation.  
This  can  lead  to  escalation  in  insulin  resistance,  endothelial  dysfunction,  hypoxia  and 
inflammation in the adipose tissue as the number of tissue macrophages and hypertrophied 
adipocytes increase. The mechanisms through which the macrophages are initially recruited are 
thought to  be various:  The macrophages  are  hypothesized  to  respond to  the  presence of 
necrotic adipocytes in the adipose tissue due to increased hypoxia after adipocyte hypertrophy, 
to the presence of increased local levels of FFAs that may “leak” from hypertrophic adipocytes 
due to their efficiency limitations in the re-esterification process after lipolysis during fasting 
states.  
These are thought to activate and polarize inflammation levels of macrophages through toll-
like  receptor  4  (TLR4)  activation  (49,50),  in  a  phenomenon  recently  dubbed  as 
“metaflammation” (51), which is also thought to be a primer for the increased inflammation 
levels and macrophage recruitment seen in dysfunctional adipose tissue.  
Metaflammation may also be a result of endoplasmic reticulum (ER) stress, a phenomenon 
that occurs when the endoplasmic reticulum, in which all the secretory and membrane proteins 
are assembled into their secondary and tertiary structures, and where unfolded or mis-folded 
proteins are detected, removed  and degraded by the 26S proteasome system (52) is subjected 
to an overload of unfolded proteins which results in the activation of an Unfolded Protein 
Response (UPR) to preserve ER function. This response, which can also occur due to metabolic 
overload in adipocytes and can be observed experimentally (53) by drug-induced impairment of 
ER function which mainly occurs through signalling pathways that inhibit insulin signalling such 
as the NF-κB pathway (52,54),  and promote an autophagic response, which if impaired (as can 
be seen in obesity (55)), may result in necrotic adipocyte death. Studies in mice show increased 
ER stress gene expression in diet-induced obesity, and the resulting inflammatory pathway 
activation in adipocytes (56), therefore suggesting a role for ER stress in insulin resistance and 
adipose tissue dysfunction. 30 
 
 
 
Figure 8: Adipose tissue remodelling in obesity (A: "healthy" expansion B: "pathological" 
expansion) (Source: (50)) 
 
The imbalance between adipocyte hypertrophy and hyperplasia, and the impairment in  
adipocyte turnover rate (57) favouring hypertrophy over hyperplasia (58) in the tissue has been 
implicated in the development of insulin resistance and a pathological development of obesity 
related comorbidities. This proposed dichotomy between “healthy” and “pathological” adipose 
tissue expansion (As shown in Figure 8), with the recruitment of new adipocytes and resulting 
beneficial angiogenesis is thought to be a central focus of the maintenance of insulin sensitivity, 
as opposed to the pathological expansion of the tissue involving adipocyte hypertrophy and 
poor remodelling of the tissue as a result of this (50).  
The  mechanistic  cause  for  the  choice  of  hypertrophy  over  hyperplasia  in  pathological 
adipose tissue expansion is still unknown. Although animal studies have suggested that factors 
such as macrophage recruitment into the adipose tissue, as occurs temporarily after significant 
weight loss, as well as  the effect of lipolysis-inducing drugs such as  β-adrenergic receptor 31 
 
agonists in mice (50), the real mechanisms behind the choice of the adipose tissue to expand its 
existing adipocyte population rather than recruit new ones through adipogenesis from its pre-
adipocyte population still remains unclear. The beneficial effects seen in the use of PPAR-γ (a 
nuclear receptor that has a major role in adipogenesis gene regulating) agonist drug family, the 
thiazoledinediones, in the treatment of insulin resistance could also show the importance of 
hyperplasia over hypertrophy (59).  
As also referred to by Figure 8, the recruitment of specific types of macrophages in the two 
different models for adipose tissue expansion, an already extensively observed phenomenon 
(60) could be an important aspect to consider when observing the different ways the tissue can 
expand, including a pathological expansion type.   
Macrophage polarity in tissue remodelling, namely looking at subtypes of the cells which 
can  be  observed  according  to  activation  state  (61).  M1(a  more  pro-inflammatory  form  of 
macrophage, actively secreting pro-inflammatory cytokines and antigen-presenting molecules) 
and M2 macrophages (a less inflammatory subtype which is associated more closely with tissue 
remodelling), is an aspect which is being extensively explored and characterised in adipose 
tissue  as  well.  There  are  interesting  results  associated  with  activation  states  such  as  the 
association of more pro-inflammatory M1 macrophages with a hypoxic state of the adipose 
tissue  (62),  and  the  alteration  of  the  more  anti-inflammatory  M2  macrophage  phenotype 
following adipocyte necrosis (63).  
The  mechanisms  behind  the  shifts  in  polarity  are  still  being  characterised,  with  the 
aforementioned hypoxic state, the necrosis of surrounding adipocytes and a specific lipid profile 
also being explored as a possible contributing factor (64) to polarity shifts, which could be 
correlated to the inflammatory differences observed in adipose tissue between the insulin 
resistant state and the healthy state of obesity. 
Another aspect that has also been explored is the difference in angiogenic potential of the 
tissue itself, which has already been shown to be different between adipose tissue depots (50). 
Whether impaired angiogenesis could be a rate-limiting step in the expansion of the adipose 32 
 
tissue or there may be “improper” vascularization of the adipose tissue occurring, as suggested 
by evidence showing omental adipose tissue in humans to have higher vascularization but more 
hypoxia (50), is still being investigated . Since there is direct evidence that hypoxia causes an 
increase in pro-inflammatory adipokine secretion, this is an important factor to consider when 
exploring adipose tissue remodelling (65). Nevertheless, the resulting insulin resistance caused 
by the improper function of the adipose tissue during obesity makes adipose tissue an important 
player in the development of obesity related comorbidities and the study of adipose tissue 
dynamics in obesity can give extraordinary insight to the metabolic problems arising from 
obesity and insulin resistance. 
1.4.3 FFA and insulin resistance in adipose tissue 
Obesity in humans is characterized by a greater amount of FFAs in the circulation (59), and 
the presence of heightened levels of FFAs as well as an impaired glucose metabolism in lean, 
healthy individuals with family histories of type-2 diabetes (59) suggests that there could be a 
vital role of FFAs in the development of insulin resistance. Their effects on skeletal muscle and 
liver insulin resistance have been discussed earlier in this report, and being the main long-term 
storage source of FFAs, the adipose tissue in this case yet again plays a central role.  33 
 
 
 
Figure 9: Role of lipotoxicity via adipose tissue FFAs in obesity (Source: (59)) 
 
The central role of FFAs in the development of insulin resistance (see Figure 9), again points 
to a pivotal role for adipose tissue, mediated by adipocyte hypertrophy, ER stress, necrosis and 
inflammatory  signalling  pathway  activation  leading to  a  change  in  the  secretory  profile  of 
adipokines  from  less  anti-inflammatory  to  more  pro-inflammatory.  Additionally,  the 
development of resistance to the anti-lipolytic effects of insulin signalling causing heightened 
levels  of  local  FFAs  could  also  exacerbate  macrophage  infiltration  due  to  TLR4  signalling 
activation (66). This in turn could exacerbate insulin resistance, causing a further increase of 
systemic FFA levels that are shown to affect other insulin-sensitive organs of the body, changing 
them to a more insulin-resistant state.   
Therefore, an imbalance in the lipolytic potential of the adipose tissue could give rise to 
insulin  resistance  from  a  metabolic  point  of  view,  and  not  just  that  of  an  inflammatory 
phenomenon as the initial trigger for adipose tissue insulin resistance. Since the activity and 
regulation  of  fatty  acid  desaturase  enzymes  such  as  Stearyl-CoA-desaturase  1  (SCD1)  that 34 
 
convert saturated free fatty acids (SFA) to mono-unsaturated fatty acids (MUFA) in adipose 
tissue which are known to be less inflammatory (59,66,67) has also been associated with insulin 
signalling (67), the metabolic component of adipose tissue dysfunction becomes an extremely 
important aspect of obesity and the development of obesity related comorbidities. 
1.4.4 Obesity or metabolism? The need to explore the heterogeneity of obesity 
The  dynamics  and  mechanisms  of  adipose  tissue  remodelling  and  dysfunction, 
inflammation, hypoxia and lipotoxicity in obesity have been explored mainly by comparing the 
adipose tissue from healthy, lean individuals to that of obese subjects, as the natural progression 
into the obese state via excess energy intake. The arising heterogeneity in insulin sensitivity (68) 
that have been observed in various obese and morbidly obese populations may point to the fact 
that metabolic syndrome is not a direct and inevitable consequence of excess energy intake, 
and that there are individuals that maintain a normal metabolic profile regardless of their 
morbid obese state (69).  This could give precious insight not only into the subtle mechanisms 
that may come into play in the obese individual but also in lean, insulin resistant individuals and 
in the metabolism as a whole.  
 
1.5 Heterogeneity of insulin resistance 
1.5.1 Metabolically Healthy Obese (MHO) individuals 
The importance of insulin resistance as a driving factor for the onset of obesity related 
comorbidities is significant, as previously described in section 1.4. However, the incidence of 
insulin  resistance  among  obese  and  morbidly  obese  individuals  is  variable  in  different 
population groups (68) and groups of individuals, regardless of their obese or morbidly obese 
status that exhibit normal insulin responsiveness is apparent (69–72). These individuals, the 
“Metabolically Healthy Obese” (MHO), despite their obese state have favourable metabolic 
profiles  with  normal  insulin  responsiveness,  lipid  and  inflammatory  profiles  and  are 
normotensive. Conversely the majority of obese and morbidly obese individuals that develop 35 
 
unfavourable metabolic profiles, insulin resistance and comorbidities have been referred to as 
the “pathologically obese” (PO) (69). A summary of MHO characteristics reported in various 
studies are shown in Figure 10. 
 
 
Figure 10: Profiles of MHO vs. MAO (PO) patients (Source: (73)) 
 
The reported prevalence of MHO depends, at least in part, on the stringency of the criteria 
used to describe the phenotype and varies from 10-40% (73). Even so, the evidence that there 
is such a phenotype, in diverse age ranges from 20 to 80 years suggests that the metabolic 
changes and this dichotomy is present, albeit changed in its proportions, in many populations 
that have been studied (74).  
There is yet a consensus to be found as to how to characterize these individuals in patient 
populations, especially with respect to relevant diagnostic techniques and biomarkers. One 
reason for these discrepancies is that the gold-standard technique for the determination of 
insulin resistance, the euglycaemic-hyperinsulinaemic clamp, is too invasive, expensive and time 36 
 
consuming  a  procedure  to  be  considered  for  routine  use  in  a  clinical  context,  therefore 
increasing the need for finding easier, less invasive methods and biomarkers for characterizing 
the phenotype(73), especially since the incidence of these individuals may vary according to the 
criteria used to select them (75). Nevertheless, the overlapping criteria amongst most research 
groups studying the phenomenon are fasting plasma glucose and insulin levels, HOMA-IR index, 
and lipid profiles such a cholesterol and triglyceride levels (73). Using these criteria it is apparent 
that this metabolic heterogeneity is still present within the obese populations.  
1.5.2 Implications of MHO individuals in the clinical setting 
The acceptance of the existence of the MHO phenotype comes with practical consequences 
to clinical care. Is there such a thing as a metabolically healthy obese individual? Can he/she be 
described as healthy despite the obese state being described as sub-optimal to health?  Is it 
worth treating these individuals in the same way as the other types of obese patients? The 
phenomenon is creating varying opinions with respect to treatment (76,77) from a practical 
perspective, but the general consensus about these assessments is that the lack of a common 
definition undermines the practical aspects of clinical care for these patients, especially with a 
lack of detailed longitudinal studies in exploring the long term effects of treatment in the MHO 
versus the PO. 
The evidence of improvement in weight loss with respect to diet and exercise therapy on 
insulin sensitivity is apparent (77), and studies have shown that exercise alone can improve 
insulin signalling and sensitivity in the tissues involved (78). However, data on the effectiveness 
of exercise and diet for improving insulin sensitivity in MHO individuals is scarce. There are 
studies that show an increase in insulin sensitivity after weight loss in PO individuals, as opposed 
to  a  slight  worsening  of  insulin  resistance  in  the  MHO  population,  showing  that  specific 
differences must be taken into account with respect to treatment for these individuals (79)., 
Another study by Shin et al. showed an improvement in inflammatory markers and lipid profiles 
of MHO women after weight loss, proving diet restrictions to be more effective in MHO women 
than PO women (80). Karelis et al. (81) showed that dietary/calorie restriction mediated weight 37 
 
loss in MHO women led to a more unfavourable insulin resistance profile than with at-risk 
individuals.  A  positive  change  in  insulin  sensitivity  and  cardio  metabolic  risk  factors  was 
observed in Janizewski et al. (82) for both MHO men and women as opposed to previous findings 
after weight loss through diet or exercise. However, with only these few studies outlining the 
dynamics of weight loss in these MHO individuals it is not enough to come to a decision as to 
what is the most effective treatment for them (83). Therefore additional research needs to be 
carried out in order to see the differences with larger patient groups and with more follow-up 
data to prove whether weight loss is the most effective means to manage the continued status 
of MHO individuals and prevent worsening of the metabolic profile.  
Surgically assisted weight loss has become one of the most effective ways of managing 
morbid  obese  patients  in  the  developed  world,  and  bariatric  surgeries  have  been  steadily 
increasing in the UK to about 6520 per year for both men and women (4).  The proof of its 
effectiveness at ‘treating’ type 2 diabetes in morbidly obese populations is documented (84), as 
well  as  reducing  overall  mortality  in  morbidly  obese  patients  (85,86).  Its  effectiveness  at 
improving an MHO metabolic profile is much less studied: with only a single study reporting 6 
month follow-up information regarding an MHO/PO population of morbidly obese patients 
carried out by Sesti et al. (87). This study showed that regardless of insulin sensitivity, which was 
supposedly better in the MHO individuals to begin with, the MHO subgroup of morbidly obese 
patients showed a significant weight loss and improvement in cardio metabolic risk markers 
compared to before gastric banding. At the same time, recent developments from the Swedish 
Obesity Study (SOS) in which 2,010 morbidly obese patients undergoing bariatric surgery were 
matched up to an equal population of patients receiving standard medical care, and the results 
indeed  showed  a  reduced  prevalence  of  cardio-metabolic  abnormalities,  although  it  was 
recognized that surgical benefits of bariatric surgery did not correlate with baseline BMI or post-
operative weight loss, and the only predictive factor for cardiovascular events was fasting insulin 
levels suggesting that insulin resistance, and not obesity, being important for the development 
of cardiovascular comorbidity (88).  Also, recent data from the American NHANES III study has 38 
 
shown that despite the lack of a common definition for metabolically healthy obesity, by looking 
at commonly used diagnostic criteria for MHO status used more frequently, the varying MHO 
population still did not seem to exhibit the same all-cause mortality risk as the remaining 
unhealthy obese patients (89).  
 Therefore, the conclusion that can be drawn from these human studies is that healthy 
metabolic profiles, even in the morbidly obese, have less immediate benefit to gain from 
bariatric surgery than insulin resistant ones, and this could be a very solid reason to discern MHO 
patients  from  PO  patients  in  a  clinical  context,  in  order  to  decide  different  therapeutic 
approaches for the two groups by also looking at how this  group of patients  avoid metabolic 
abnormalities across various BMI and age ranges. The varying evidence from this field of study 
is also a clear signal that more is needed to understand the phenomenon and learn from the 
different metabolic profiles of the patients in order to target specific mechanistic differences 
involved in the onset of the PO phenotype. 
1.6 Mechanistic causes for MHO vs. PO differences 
1.6.1 Adipokine profile differences 
The differences in the secretory profile of adipose tissue with respect to its expansion could 
suggest an inherent difference in the levels of specific circulating adipokines such as resistin 
(associated with increased insulin resistance), adiponectin (known to be an endogenous insulin 
sensitizer) and TNF-α (associated with insulin resistance), all of which have been seen to be 
altered in the presence of insulin resistance in humans (90).  Since these and other adipokines, 
like IL-6, all have autocrine and paracrine effects on glucose metabolism, lipolysis and insulin 
sensitivity (43) they could be different between MHO and PO in their levels and effects on insulin 
resistance and local inflammation.  A difference in secretion levels of these adipokines could 
also be used as a biomarker for the onset of insulin resistance and the metabolic syndrome, 
which makes quantification of these adipokines and their metabolic effects important. Ratios of 
adiponectin  to  HOMA-IR  index  have  already  been  used  as  a  predictive  tool for  metabolic 39 
 
syndrome in humans (91), and adipokine levels have been observed during weight loss (92), 
making the need for a biomarker that could distinguish MHO/PO patients important.  
1.6.2 Inhibition of Adipogenesis 
The possible mechanisms for the differences between the MHO and PO phenotype are being 
explored at the molecular level.  Adipocyte hypertrophy has been reported in the subcutaneous 
adipose tissue of human patients as being predictive for type 2 diabetes (93).  Similarly adipocyte 
hypertrophy has been shown in certain ethnic groups such as Pima Indians (58) and South Asian 
populations more prone to insulin resistance (94). Also hypertrophied, older adipocytes had 
been associated with insulin resistance and adipogenesis-associated genes are more poorly 
expressed in the adipose tissue of type-2 diabetic compared to non-diabetics (95,96). This 
inhibition of adipogenesis in insulin resistant adipose tissue is worthy of further exploration. 
However data from various studies are inconclusive: some confirm the hypothesis that MHO 
patients have smaller adipocytes in various depots (yet with the omental being the only depot 
to  be  significantly  correlated  to  the  metabolic  syndrome  (97)),  with  lower  expression  of 
adipogenesis-inhibiting genes such as preadipocyte-factor 1 (PREF-1) in MHO patients. These 
data suggest an inhibition of adipogenesis in PO adipose tissue (98). Other studies point towards 
smaller adipocytes in both depots, despite impaired adipogenesis, as the possible cause of the 
difference between MHO and PO individuals.  The emergence of studies also pointing towards 
lower PPARγ expression in adipocytes either caused by inflammatory cytokines (99), or even 
xenobiotic molecules present in western diets such as naringenin (100) shows that a variety of 
factors can affect healthy adipocyte turnover and that the exploration of this difference is 
important  to  understanding  metabolic  variability.  Also,  an  association  between  smaller 
adipocyte size and heightened local inflammatory signalling has been observed in some studies 
(101,102).  This  is  contrary  to  the  suggestion  that  inhibition  of  adipogenesis,  adipocyte 
hypertrophy and necrosis could lead to local inflammation (48). These differences in data could 
arise from the different criteria used to select patients for the two groups, MHO and PO, 
therefore making the need for a common definition ever more important.  40 
 
1.6.3 Dysfunction in the regulation of SREBP Proteins and the lipogenic/lipid homeostasis 
pathway 
Lipogenesis and cholesterol homeostasis stimulated by insulin signalling in adipose tissue 
appears to be mediated by the transcription factor Sterol Regulatory Element-binding Protein 
1-c (SREBP-1c) (103). This factor is a member of a family of three transcription factors, with the 
most prevalent one in adipose tissue being SREBP-1c. The SREBP-1c transcription factor is 
responsible for transcriptional activation of the entire monounsaturated fatty acid synthesis 
pathway (103), and is also activated during the adipocyte differentiation process (104). The 
regulation  of  SREBP-1c  is  complex  and  involves  steps  at  the  transcriptional  and  post-
translational levels with initial transcripts encoding a membrane-bound precursor protein kept 
anchored to the endoplasmic reticulum via Insig proteins. When sterol depletion ensues the 
Insig proteins dissociate from SREBPs, allowing them to translocate to the Golgi apparatus 
where they are cleaved by proteases, and the N-terminal fragment of the SREBP is cleaved from 
the membrane and can finally translocate to the nucleus to regulate gene transcription (105), 
which involves several genes involved in fatty acid metabolism (see Figure 11). Regulation of 
SREBP levels by insulin signalling is supported by various pieces of evidence. Rat hepatocytes 
express higher levels of SREBP-1c after insulin treatment, as well as decreasing SREBP-1c levels 
after streptozotocin-induced diabetes in rat hepatocytes  (106). Insulin also induces liver X 
receptor which in turn is known to activate SREBP-1c transcription (107), therefore linking 
insulin and insulin resistance to the possibility of improper lipid homeostasis, specifically with 
cholesterol levels (108). 
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Figure 11: Genes regulated by SREBP activity in cholesterol and fatty acid synthesis 
pathways (Source:(105)) 
 
The discovery that dietary fatty acids such as ω-3 and ω-6 polyunsaturated fatty acids 
(PUFAs) are responsible for the down-regulation of the SREBP transcription factors in mouse 
livers (109), as well as the evidence showing that overexpression of SREBP-1c in mouse white 
adipose tissue led to an insulin-resistant phenotype of hypertrophied adipocytes in the adipose 
tissue  of  mice  (110)  suggest  that  a  possible  difference  in  metabolic  regulation  of  lipid 
homeostasis maybe due to diet or genetic factors, leading to adipocyte hypertrophy due to 
excess lipid accumulation, and inhibition of adipogenesis by SREBPs  as well as its target lipid 
metabolism genes like SCD1. 
1.6.4 The need for a biomarker 
As previously mentioned, studying and gaining an understanding of the differences in the 
local functioning of the adipose tissue can also be useful for determining a viable and detectable 
biomarker for the recognition of specific metabolic profiles. Despite the previous studies cited, 
there is still a difference in opinions as to whether the actual use of high molecular weight 
adiponectin or other adipokines such as C-reactive protein can give an indication of metabolic 42 
 
status (111).  Other types of biomarker types, namely neurotransmitters like epinephrine (112), 
are under study for their effects on the function of the adipose tissue and will be discussed in 
the next section of this thesis, or specific circulating serum microRNA types (113) which have 
been observed to be altered during the onset of insulin resistance and type 2 diabetes (114), 
and of which the signalling properties are only just being explored in these past years.  Once a 
common definition for MHO is agreed upon and a common biomarker found, the process of 
discrimination could allow for a more stratified and accurate approach to the clinical treatment 
of obesity. 
 
1.7 Sympathetic nervous system activity and metabolism 
1.7.1 The sympathetic nervous system in breathing and blood pressure control 
Blood pressure (BP) in humans is regulated by two concerting factors: vascular resistance 
and cardiac output. Both are directly controlled by the autonomic nervous system through 
specific mechanisms which not only determine the initial “set point” for basal pressure levels 
but also react to changes in the external environment that require homeostatic regulation (115).  
One of the most studied parts of the autonomic nervous system, specifically due to its activity 
regarding the regulation of blood pressure and its relevance in hypertension is the sympathetic 
portion, the SNS (116). The SNS controls the level of blood pressure in the body via three main 
types  of  neurons  activated  by  different  stimuli,  barosensitive,  thermosensitive  and 
glucosensitive, which innervate the circulatory system, the heart, the kidneys and the adrenal 
medulla. Barosensitive sympathetic neurons are under the control of arterial baroreceptors in 
the carotid body. This large group of neurons is chiefly responsible for both short-term and long-
term BP regulation and its level of activity at rest is thought to be the most important parameter 
for long-term BP control (116). 43 
 
 
 
Figure 12: Sympathetic control of BP in humans. 
Black arrows indicate external factors, green arrows interactions in the network. SFO = 
Sufornical organ OVLT = organum vasculosum lamina terminalis NTS = nucleus tractus 
solitarius AP = area postrema Ang II = Angiotensin II SPGN = sympathetic pre-ganglionic 
neuron SGN = sympathetic ganglionic neuron (Source: (116)) 
 
The core sympathetic network responsible for BP control in the human body is summarized 
in Figure 12, which comprises of three main neural control networks (all responsive to various 
types of circulating hormones): the Hypothalamus, the Nucleus of the Solitary Tract (NTS) and 
the Rostral Ventrolateral Medulla (RVLM). These are responsible for relaying external inputs 
(mainly from the renin—angiotensin system which will be discussed later in this introduction) 
and responding via the spinal cord ganglionic neurons in eliciting the change in blood pressure 
via the control of heart rate, vascular contraction or sodium retention by the kidneys  (115,116).  
Elevated SNS activity concerted with hypertension has been observed as a common occurrence 
for decades (117), and dysfunction in sympathetic tone appears to be caused by other obesity-
related  comorbidities  such  as  obstructive  sleep  apnoea  (21).  This  correlation  between 
sympathetic nervous system activity, obesity and hypertension makes the study of how brain 
stem control mechanisms in general are affected in the obese state, and the onset of obesity-
related comorbidities extremely important. 
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1.7.2 The sympathetic nervous system and adipose tissue 
Adipose tissue is innervated by the sympathetic nervous system, which is responsible for 
the stimulation of lipolysis in the tissue during fasting and exercise conditions (118,119). The 
presence of sympathetic neuron fibres in adipose tissue has been observed histologically and 
via in situ hybridisation for quite some time (120), and the main neurotransmitters responsible 
for lipolysis stimulation, namely adrenaline and noradrenaline (NA), have effects on adipose 
tissue lipolysis via adrenoceptors present on adipocytes (121).  
The lipolytic pathway is mediated by the expression of these adrenoceptors as previously 
shown by studies carried out by Langin and Lafontan (118), with β2 adrenoceptors being the 
lipolytic mediator of noradrenaline signalling whereas α2 adrenoceptors act in an anti-lipolytic 
fashion.  
 
 
Figure 13: The HPA axis. CRH = Corticotropin releasing hormone, AVP= Vasopressin, 
ACTH = Adrenocorticotropic hormone (Source: (122)) 
The presence of sympathetic neurons also appears to co-localise with other neuropeptides 
in  the  adipose  tissue,  such  as  neuropeptide  Y.  The  correlation  between  SNS  activity  and 45 
 
metabolic function observed through the innervation and the activity of the SNS during the 
stimulation of lipolysis leads to many questions regarding a possible link between stressors, 
metabolism and the Hypothalamic-Pituitary-Adrenal (HPA) axis, shown in Figure 13.  
The reason why these questions make the HPA axis so important is due to its differential 
function in obesity and visceral obesity (123–125), and its direct link with gluconeogenesis 
mediated by the liver (126), which could be altered by chronic stress levels and other mediators 
of chronic SNS activity in stress, such as neuropeptide Y.  
The HPA axis is the main endocrine pathway responsible for the stress response consisting 
of CRH release from the hypothalamus, which in turn causes ACTH release from the pituitary 
and ultimately the release of glucocorticoids from the adrenal cortex. Since glucocorticoids 
affect adipose tissue as mediators of lipolysis via the activation of lipolytic enzyme activity such 
as Lipoprotein Lipase (LPL) (127), levels of circulating glucocorticoids (and other mediators of 
stress and SNS activity) mediated by chronic stress are a link between the HPA axis, metabolism 
and  the  obese  state.    Therefore  circulating  glucocorticoids  could  be  important  in  the 
understanding of metabolic differences between individuals in an obese or morbidly obese 
population. 
 
1.7.3 Direct effectors of the SNS: catecholamines and adrenoceptors 
Catecholamines such as noradrenaline are the neurotransmitters of the SNS. The synthesis 
of these catecholamines are carried out by a number of enzymes such as tyrosine hydroxylase 
(TH) in SNS neurons which can be histologically stained to reveal innervation in tissues, including 
adipose tissue (128,129). 
The effects of catecholamines on adipose tissue lipolysis has been extensively studied, 
especially  in  WAT  (130).  The  signalling  pathway  involved  in  the  regulation  of  lipolysis  is 
summarised in Figure 14.  46 
 
 
 
Figure 14: lipolysis pathway. 
AC = adenyl cyclase, cAMP = cyclic AMP, PKA = protein kinase A, HSL = hormone-sensitive 
lipase, TG = triglyceride, DG = diglyceride, MG = monoglyceride, AMPK = 5’ AMP activated 
protein kinase, ATGL = adipose triglyceride lipase (Source: (131)) 
 
Noradrenaline binds to the β-adrenoceptors of the adipocyte is through the activation of 
the G-protein coupled receptors responsible for adenyl cyclase activation, resulting in a build-
up  of cytosolic cyclic  AMP  and the  resulting  activation of  protein  kinase  A, which  in  turn 
phosphorylates  hormone-sensitive  lipase  (HSL)  activating  the  enzyme  responsible  for 
triglyceride breakdown, which results in the release of non-esterified (free) fatty acids and 
glycerol into the circulation. Within the cell the triglycerides are stored in the cytoplasm in lipid 
droplets surrounded by phosphorylated perilipin (118,127). This regulation of lipolysis denotes 
a direct effect of the SNS on the adipose tissue, and shows an important link between nervous 
system function and metabolism. 
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1.7.4 The role of astrocytes in the sympathetic nervous system 
Since their shift in recent years from simple structural and maintenance-related cells of the 
nervous system to active participants of nervous system function, astrocytes have now become 
important players in neurology, with their role as metabolic suppliers to neurons and mediators 
of long-term potentiation (LTP), as well as integral parts of synaptic transmission maintenance, 
to the point where the theory of a “tripartite synapse” composed of the astrocyte as well as the 
classical two pre- and post-synaptic neurons is becoming widely accepted (132–135).  
 
 
Figure 15: Models of metabolic coupling in the neuron/astrocyte interaction (source: 
(136)). 
 
The metabolic role of the astrocytes, since the discovery of the highly capable glycolytic 
potential of the cells and the presence of specific lactate and glucose transporter proteins (GLUT 
family for glucose, MCT family for astrocytes both shown in Figure 15A) both involved in the 
supply of glucose and lactate involves two theories: a conventional model, (shown in Figure 15B) 
of neuronal energy supply which is thought to involve the direct use of glucose by the neuron 48 
 
(therefore presuming a predominantly glycolytic metabolism in the astrocyte) and the resulting 
uptake of lactate as a waste product by the surrounding astrocytes or a “lactate shuttle” model  
(Figure  15C)  by which the  astrocyte  shuttles  lactate  into  the  neuron  (allowing  a  neuronal 
metabolism centred more towards the TCA cycle) after carrying out its own glycolytic cycle to 
produce lactate for the neuron (135,136). Glycogen stores previously described in astrocytes 
(137)  are  degraded  into  lactate  directly  inside  the  astrocyte  during  hypoglycaemia  and 
noradrenaline stimulation (138), and experiments have linked synaptic activity to lactate uptake 
in the neurons via MCT2 lactate transporter proteins (136).   
The opinion of the scientific community with respect to the astrocyte’s role in the neural 
circuitry of the CNS dramatically changed with the discovery of oscillatory intracellular calcium 
responses to specific neurotransmitters like glutamate (139), as well as the communication of 
astrocytes and neurons via these calcium oscillations (140). Further, the discovery of molecules 
secreted by the astrocytes that would affect synaptic function, dubbed “gliotransmitters”(141), 
solidified the hypothesis that this cell type was more than just “structural scaffolding” for the 
other components of  a neural circuit, but was much more involved in the function of the 
synapse  as  well  as  brain  circulation  and  blood  supply  in  the  blood  brain  barrier  (141). 
Intracellular Ca2+ oscillations occur through a variety of stimuli that the astrocytes are subjected 
to,  from  mechanical  stress  to  specific  hormone  responses  elicited  by  receptors  that  are 
expressed on the cell membrane such as peptide receptors (142), as well as purinergic ATP 
receptors (143).  
Oscillatory patterns in these astrocytes also are amplified by the interconnected nature of 
the cells themselves with neighbouring cells of the same type, since astrocytes are known to 
propagate the calcium oscillation “waves” via the expression of gap junction proteins such as 
connexins Cx30 and Cx43 (144), as well as metabolites such as glucose which has been observed 
as moving in between cytoplasms via connexin channels in hypothalamic astrocytes (145). This 
intercellular signalling is beginning to be studied for its possible control over neural networks 
responsible for central nervous system functions, such as breathing control. studies show (146) 49 
 
cyclical activation of astrocyte calcium signalling, preceding inspiratory movement in the pre-
Botzinger complex (an area of the ventrolateral medulla involved in breathing patterns during 
sleep) which regulate inspiratory neuronal output.   
 
 
 
 
Figure 16: Possible pathways of astrocyte chemo-detection in the ventral surface of the 
medulla oblongata (VMS). 
Cx = connexin hemichannel, RTN = retrotrapezoid nucleus, CPG = central pattern 
generator (Source: (134)) 
These data Gourine et al. (134,143)  suggest that astrocytes have a very important role in 
the chemo detection of changes in CO2 content of the blood, and do so in an independent 
manner compared to neuronal activity of the brain stem. The putative way that astrocytes of 
the brain stem do so is shown by Figure 16, where changes in blood acidity caused by a rise in 
circulating CO2, are detected in a resulting acidification of the cell’s surrounding environment, 50 
 
and is detected by the astrocytes (134), causing the opening of connexin hemichannels that 
release ATP in adjacent astrocytes. If the hypercapnic conditions persist, intracellular calcium is 
released after connexin hemichannels close and ATP release persists via exocytosis which acts 
in an autocrine and paracrine manner spreading Ca2+ excitation and enhancing ventilation by 
activating chemosensory neurons (RTN and CPG neurons). ATP may not be the sole player in the 
mechanism  since  other  gliotransmitters  are  known  to  be  released  in  response  to  Ca2+ 
oscillations (140), and may affect respiratory networks in a long-term stimulatory change, so 
their role in central nervous system regulation of breathing appears to be in need of elucidation.  
Another interesting aspect surrounding astrocyte regulation of neuronal networks is the 
possible link between peripheral hormone secretion of organs such as the  adipose tissue, with 
the release of leptin being important in the homeostatic CNS regulation of feeding stimuli in 
humans and the presence of astrocyte activity in response to leptin (147,148) in CNS areas 
responsible for the control of food intake such as the hypothalamus. This allows for possible 
hypotheses regarding the excitability and long-term plasticity of neuronal networks in response 
to peripheral hormones and the effects of peripherally secreted molecules in the functioning of 
the CNS itself, past the current understanding of the concept.  
The role that chemosensing astrocytes could be playing in the regulation of higher functions 
of the CNS at the level of the medulla oblongata is clear. However, what the inherent signals 
from peripheral organs could be using to influence the RVLM to steer it away from its normal 
function are still to be elucidated, and were studied as part of this project.  
1.7.5 Neuropeptide Y and the sympathetic nervous system 
Neuropeptide Y or NPY is a 36 amino acid peptide and a sympathetic nervous system co-
transmitter which was discovered over 30 years ago when originally isolated from porcine brain 
in 1982, studied chiefly for its role in the promotion of prolonged vasoconstriction in various 
vascular beds (149–151). The study of NPY later focused on its characteristics as a potent 
stimulator of appetite and feeding neuronal circuitry, but the aspect of its secretion being linked 
to the activation of the SNS  is poorly understood. However,  its levels are correlated with 51 
 
heightened SNS activity (evident by higher circulating catecholamines) in many studies linking 
SNS-related pathologies to high NPY levels, such as Post Traumatic Stress Disorder (PTSD) (152), 
obstructive sleep apnoea (OSA, a typical comorbidity associated with obesity) (153) and stress-
related adipose tissue accretion (154).  
 NPY is released after prolonged stimulation of sympathetic nerves. Long-term stimulation 
of the SNS (155), is commonly defined as stress on an organism. This type of release has allowed 
NPY to be studied in correlation with conditions of stress and stress responses, as well as being 
studied  as  a  link  between  a  long-term  HPA  axis  activation  due  to  increased  levels  of 
corticosteroids in the circulation in stress and high fat diets (156)  and peripheral activity in 
organs such as adipose tissue and the vasculature, which also depend on the cleavage of the 
peptide into a shorter form by the enzyme DPP-IV which affects its receptor specificity in 
peripheral tissues. These recent findings have shown that NPY is important not only as a central 
feeding signal, but a signal that has peripheral origins and effects. 
 
1.7.6 NPY and the periphery:  adipose tissue npy receptors and adipose tissue function 
NPY and its associated G-protein coupled receptor pathway has a documented range of 
effects on many different peripheral organs which has been extensively reviewed (155), but only 
relatively recently have the effects on metabolism been explored, specifically with respect to its 
activity in adipose tissue. Adipose tissue is known to produce NPY (157) as well as express NPY 
receptors 1 and 5 most abundantly (158). NPY signals may vary according to the activity of 
proteases such as DPP-IV that cleave NPY a specific sites, thus changing its receptor specificity, 
specifically  changing  it  from  neuropeptide  receptor  Y1  to  neuropeptide  receptor  Y5,  both 
commonly known to be expressed and most abundant in adipose tissue (159) . The main 
response exerted by the presence of NPY in the periphery is thought to be the inhibition of 
lipolysis (158) and the accumulation of fat mass through the stimulation of PPAR-γ expression 
in adipocytes, depending on the activity of DPP-IV which is also affected by insulin levels (159) . 
Adipogenesis also appears to be promoted by the presence of local NPY levels, and evidence 52 
 
from  in  vitro  models  suggest  that  NPY  receptor  activation  causes  an  impairment  in  the 
translocation of insulin-sensitive glucose transporter 4 (GLUT4) from the cytoplasm to the cell 
membrane (160), possibly via uncoupling of the mechanisms behind insulin-responsiveness of 
the adipocytes in individuals with higher locally secreted levels of NPY.  These data allow for the 
formulation of the hypothesis that circulating NPY levels could be affecting not only adipocytes 
at the local tissue level, but also the regular function of the brain stem RVLM. 
Another interesting aspect of NPY and adipose tissue interactions between the CNS and 
peripheral  organs  comes  with  the  known  involvement  of  central  NPY  signalling  in  the 
hypothalamus and its effect on the development of brown adipose tissue (BAT). BAT is an 
adipose tissue variant initially thought to be solely present in animal models and recently 
characterised as present also in humans (161) chiefly responsible for the dissipation of energy 
in the form of heat through the use of mitochondrial proton gradient disrupting proteins such 
as UCP1.  
Brown adipocyte development has also been shown to be inducible from white adipose 
tissue cells and mesenchymal stem cells by signalling pathway regulation (162), and therefore 
achieved  importance  as  a  possible  therapeutic  target  for  abnormal  energy  expenditure  in 
obesity.  With  evidence  also  showing  that  the  knockdown  of  NPY  gene  expression  in  the 
hypothalamus causes an increase in the development of brown adipose tissue in rats (163), and 
the direct link between noradrenergic signalling and brown adipose tissue development and 
trans-differentiation (161), it becoming more and more clear that NPY could be an even more  
important player in the field of adipose tissue biology and a possible therapeutic target in 
obesity. 
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1.8 Hypothesis and aims of the study 
1.8.1 Hypothesis: NPY as a possible link between periphery and CNS 
 
 
Figure 17: Possible hypothesis for SNS interference with energy homeostasis and BP 
regulation 
Emerging evidence of NPY as a mediator of a variety of effects on peripheral organs, as well 
as on the central nervous system (155) has led to the hypothesis that there is a direct effect of 
elevated peripherally (adipose tissue)-derived NPY, perhaps consequent to increased stress- 
associated activity of the SNS, on the functioning of the CNS, mediated by astrocytes of the 
RVLM.  This effect is summarised in Figure 17. Further, it was postulated that the astrocytes, 
through the modulation of intracellular signalling pathways, mediated the functioning of the 
neuronal circuits of the brainstem. This is in keeping with observations that obesity-related 
comorbidities, such as obstructive sleep apnoea (OSA), are associated with increased levels of 
circulating NPY (153,164) in the presence of greater SNS activity (20). This is supported by data 54 
 
that peripheral NPY increases with stress and affects adipose tissue metabolism and vasculature 
(165), and that chronic elevation in circulating NPY impairs baroreflex sensitivity, as seen in 
human OSA cases (21,166). This could indicate a direct involvement of peripheral NPY on the 
normal function of brain stem astrocytes. 
Hypothesis 
That the presence of heightened NPY levels secreted from the central nervous system and 
peripheral tissues of an obese organism could be an additional mechanism partly responsible 
for the differences in comorbidities associated with the morbidly obese state between PO and 
MHO individuals 
To be studied by the following aims: 
1.8.2 Overall aims 
1.  To identify an normoinsulinemic/insulin sensitive morbidly obese Caucasian patient 
cohort  
2.  Compare differences in NPY levels, in the circulation and adipose tissue, between the 
normoinsulinemic and hyperinsulinemic subjects 
3.  Explore the hypothesis that elevated circulating peripheral NPY causes metabolic and/or 
inflammatory abnormalities in an in vivo rat model or in vitro model of primary human 
fetal brain stem chemo-sensing astrocyte cell line. 
1.8.3 Patient recruitment and characterisation 
The differences between MHO and PO individuals of the same ethnicity were explored in a 
clinical setting and described according to already described criteria used in the literature. This 
was  carried  out  in  order  to  identify  a  normoinsulinemic/insulin  sensitive  morbidly  obese 
Caucasian patient cohort and to investigate the effect of weight loss in this normoinsulinemic 
group versus hyperinsulinaemic groups. This characterization was then further used for more 
detailed studies at the tissue level.   55 
 
1.8.4  Assessment of adipokine differences and search for possible biomarkers 
 These characterised groups were also used to compare differences in secreted adipokines, 
including NPY levels, in the circulation and adipose tissue. They were quantified to determine 
differences in their levels in the two groups of patients in order to find other possible candidates 
as a readily detectable marker for the phenotype. 
1.8.5 Differences in Morphological and local secretory function between subcutaneous (SC) 
and omental (OM) adipose tissue 
Histological and secretory differences (organ cultures) in the adipose tissue between the 
two groups of patients as an indication of the proposed variation in tissue secretory and lipolytic 
function were examined. 
1.8.6 Adipogenic/metabolic gene expression differences 
As markers of tissue remodelling, the aim was also to determine the expression of selected 
adipogenic genes in the tissue, between depots of the same patients (SC and OM) and between 
patient groups such as MHO, PO and diabetic morbidly obese individuals. mRNA expression of 
metabolically significant genes, such as SCD1, as a marker not only of the level of SREBP-1c 
signalling inside the adipocytes, but also of possible dysfunction in lipid homeostasis of the 
adipose tissue. Furthermore, the levels of NPY receptor in the tissue were also determined. 
1.8.7 Circulating NPY levels 
Circulating  NPY  levels  were  measured  as  a  biomarker  for  SNS  hyperactivity  in  the 
metabolically unhealthy (pathological obesity).  
1.8.7 Effects of NPY/NA levels simulating heightened SNS activity on human astrocytes 
By using noradrenaline and NPY, alone and in combination, the rationale was to re-create 
conditions of stress and chronic SNS activation on human brain stem astrocytes. The function of 
the  astrocytes  was  determined  by  measuring  their  release  of  inflammatory  cytokines  and 
lactate, as well as changes in intracellular signalling molecules (pSTAT3, cAMP and Ca2+).  
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Materials and Methods 
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2.1 Clinical method protocols 
2.1.1 Patient Recruitment 
 
 
 
Figure 18: Clinical study structure 
 
Patients of Caucasian background were recruited from the North London Obesity Surgery 
Service  of  the  Whittington  Hospital,  London,  UK  while  awaiting  surgical  weight  reduction 
surgery. The method of recruitment was carried out in parallel with the regular clinical protocol 
for bariatric surgery eligibility assessment (as shown in figure 18), with hospital nutritionists 
monitoring the weight loss of the patients before undergoing assessment and leading up to 
surgery. Anthropometric and clinical data as well as data regarding medication taken by the 
patients prior to surgery (with respect to the exclusion of patients taking medication from the 58 
 
MHO group) were all recorded from patient clinical notes. Prior to surgery fasting blood samples 
was taken from all patients. During surgery an abdominal subcutaneous (SC) and omental (OM) 
adipose tissue sample (2-5 gms) was obtained. All patient data was stored on an IBM SPSS 
Statistics 20 for Windows (IBM, USA) database file, and kept in compliance with protocols 
safeguarding  patient  privacy.  All  patients  gave  written  informed  consent.  The  study  was 
approved by the National Ethical Committee. 
2.1.2 Blood samples 
Serum, plasma and sodium fluoride samples were taken from each patient on surgery day 
as well as on follow-up visits 3-6 months after surgery in a fasting state, and all centrifuged at 
3000rpm for 15 minutes with supernatant collected and stored at -80°C for long-term storage. 
Plasma glucose concentration was assayed with glucose oxidase reagent (Beckman, USA Cat no. 
472500). Serum insulin levels were determined by ELISA (Mercodia, UK Cat no. 10-1113-01).  
Serum triglycerides, total, low density lipoprotein (LDL-) and high density lipoprotein (HDL-) 
cholesterol were assayed with commercial reagents with total-cholesterol and triglycerides 
tested (Roche Diagnostics, UK). LDL-cholesterol was calculated using the Friedwald formula. All 
lipid assays were performed by Dr David Wickens (Chemical Pathology, Whittington Hospital, 
London UK). Insulin resistance was calculated using the homeostatic model assessment where 
HOMA = (glucose in mmol/L x insulin in mIU/L)/22.5. 
2.1.3 MHO/PO characterisation criteria 
The patients, after being matched for age and BMI, were considered MHO based on the 
presence of the following criteria: 
•  No metabolic disorders including T2DM, dyslipidaemia and hypertension 
•  Systolic blood pressure at < 140 mmHg, diastolic blood pressure at <85mmHg 
•  Absence of cardiovascular disease 
•  Fasting plasma glucose of <6.8 mmol/l and insulin <6.5 miU/ml 
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2.2.1 Histology sample preparation 
A  0.2-0.3g  sample  from  subcutaneous  and  omental  adipose  tissue  was  excised  for 
histological purposes and incubated in neutral buffered formalin (VWR International, USA Cat 
no. 16004-126 ) for 24 hours and then transferred to 50% Ethanol (Sigma, UK) and stored at 4°C 
until processing. 
2.2.2 Hematoxylin and Eosin staining 
Slides from paraffin processed samples were placed in Gill’s 1X Hematoxylin solution 
(Sigma, UK Cat no. GHS1128), rinsed with tap water for 5 minutes, Then placed in an acid ethanol 
solution (1%HCl in 70%ETOH, Sigma UK) for 2-3 times, rinsed with tap water for 3-5 minutes and 
then dunked 5-6 times in ammonia water solution (1mL NH
4OH in 1L H
2O), and then rinsed with 
tap water again for 3-5 minutes. The slides were then placed in Eosin Y (Sigma, UK Cat no. E4009) 
for 1 minute, rinsed in tap water once more and then washed in 3x 95%, 3x 100% ETOH, 50:50 
Xylene-ETOH (Sigma, UK), and 3x 100% Xylene as the final steps before applying a cover slip. 
2.2.3 NPY/CD68 Immunohistochemistry 
Slides were washed in Tris buffered saline for 2 min and blocked at room temperature 
for 5 min in DAKO peroxidase blocking solution (Dako, Denmark Cat no. S2023) followed by 10% 
horse serum in Tris buffered saline for 10min. Primary antibody (1 in 200 dilution of affinity 
purified  rabbit  anti  human  NPY  Y1 or  Y5  receptor polyclonal  antibody:  Sigma,  UK  Cat  no. 
HPA029903 and HPA013790, or CD68 affinity purified rabbit anti human polyclonal antibody 
Dako, Denmark Cat no. M0876) was added and incubated for 60 min at room temperature and 
secondary antibody (1 in 1000 dilution of anti-rabbit IgG peroxidase conjugated antibody: Sigma 
Cat. No. A0545) for 45 min.  Detection was by standard Avidin Biotin Complex (ABC)/DAB 
method. 
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  Blinded to the metabolic status of the patient samples, for each slide (1 per depot of 
each patient) 3 images were captured using the bright field setting at 20x magnification on a 
microscope attached to a CCD camera on H&E stained slides.  
 
 
 
Figure 19: adipocyte size calculation method 
 
Images were equally sized, non-overlapping and taken at random locations on each slide. For 
each image, after increasing contrast, all completely visible and completely circular cells were 
manually counted and traced and the area calculated in pixels through the “area” function in 
Image-J (National Institute of Health, USA) as shown by Figure 18.  The pixel areas were then 
pooled according to MHO/PO status and statistical analysis was carried out on the two groups. 
2.2.5 Quantification of CD68/NPY receptor DAB stain 
Blinded to the metabolic status of the patient samples, for each slide (1 per depot of each 
patient) 10 images (5 in the case of the NPY immunohistochemistry) were captured using the 
bright field setting at 20x magnification on a light microscope (Nikon, Japan) attached to a CCD 
camera. Images were equally sized, non-overlapping and taken at random locations on each 
slide. Each image was processed in the same manner, however in order to emphasize the DAB 61 
 
staining, each photograph was de-convoluted using the appropriate function (H DAB Colour de-
convolution) in ImageJ and given an appropriate threshold value. This value was different for 
each picture. This method gave arbitrary values of zero for the images taken from the slides 
which had negative staining; and removed as much background signal as possible without 
compromising the positive staining. Once each image was processed the number of pixels was 
counted and recorded as an arbitrary value which represented a degree of valid staining for that 
particular image. The pixel values were then recorded and statistical analysis carried out. 
2.2.6 NPY blood vessel image analysis 
Blinded to the metabolic status of the patient samples, for each slide 3 images of blood 
vessels were captured, using the same criteria as above. To quantify the staining of the blood 
vessels, each vessel was graded as small, medium or large. The size allocated was determined 
by which size square the vessel fitted into best. The sizes are described in the table below: 
 
Vessel size  Square dimensions (pixels)  Area (pixels) 
Small  100 x 100  10000 
Medium  150 x 150  22500 
Large  200 x 200  40000 
 
The individual vessel was cropped and the image modified to emphasize the brown staining. 
Each image was once again given an appropriate threshold value in the same way as the CD68 
stain quantification. Once each image was processed the number of pixels was counted. This 
number was then expressed relative to the size of the vessel, by use of the following formula: 
𝐴??𝑖????? ????? ???????????𝑖?? ?? 𝑁𝑃𝑌 ???𝑖?𝑖?? ?? ????? ??????? 
= 
𝑃𝑖???? ???????  𝑖? ?ℎ? 𝑖???? ?? ?ℎ? ??????
𝐴??? ?? ?????? (?𝑖????)
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This would account for any differences in staining due to the vessel size i.e. a larger 
vessel  would  have  an  increased  number  of  receptors,  but  not  necessarily  a  greater 
concentration or density of receptors.  
 
2.3 Adipokine protocols 
2.3.1 Organ explant cultures 
Subcutaneous and omental adipose tissue explants were excised ranging from 0.049g to 
0.052g in size and incubated for 24 hours at 37°C and 5% CO2 in 500µL CellGro Complete Medium 
(Mediatech, USA Cat no. 40-101-CV) + 1% Penicillin/Streptomycin solution (Invitrogen, USA Cat. 
No.15140122). Medium and tissue were stored at -80°C for long-term use. 
2.3.2 Protein extraction 
0.5g tissue samples were ground using liquid nitrogen, mortar and pestle and extracted 
using 800μL RIPA lysis buffer (Sigma, UK Cat no. R0278), vortex-shaking and a centrifugation 
step at 14,000 rpm at 4°C, collecting the supernatant and quantifying protein content using a 
Novagen BCA Protein Assay Kit according to supplier manual (Novagen, USA Cat. No.71285). The 
protein  quantification  assay  was  carried  out  according  to  user  manual  specifications  and 
quantified using a Dynex Opsys-MR plate reader (Dynex Technologies, USA) at wavelengths 
specified by user manual. Samples were stored at –80°C for long-term use. 
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2.3.3 Circulating and local adipokine/NEFA levels 
All circulating adipokines were tested in the serum or EDTA plasma samples taken and 
measured by ELISA (R&D Systems (UK), according to manufacturer’s instructions. NPY levels in 
serum  were  assessed  by  ELISA  (Millipore,  UK  Cat  no.  EZHNPY-25K)  as  per  protocol.  Final 
absorbance was read on a Dynex Opsys-MR plate (Dynex Technologies, USA) at wavelengths 
specified by supplier manuals. Circulating non-esterified fatty acid (NEFA) levels were assayed 
using a reactive colorimetric assay (Wako Diagnostics, USA Cat. No. 999-34691, 995-34791, 991-
34891, 993-35191 and 276-76491) according to supplier manual, and analysed on a Dynex 
Opsys-MR plate reader (Dynex Technologies, USA). 
2.3.4 Induction of IL-6 secretion by IL-1β 
0.05 to 0.06g explants of subcutaneous fat from a total of 12 patients were taken in 5 
aliquots  from  an  excised  tissue  sample,  and  incubated  in  2mls  of  DMEM  +  10%FBS  + 
Penicillin/Streptomycin at 37°C and 5% CO2 (Gibco, USA Cat no. 11965-084). Medium was 
changed at 24, 48 and 65 hours from start of incubation. After 65h the medium was finally 
changed to 2 ml CellGro + Penicillin/Streptomycin in wells 1 and 2 as a control and 2ml of CellGro 
+ Penicillin/Streptomycin + 10ng/ml of IL-1β in the remaining three for 8 hours (Mediatech, USA 
Cat no. 40-101-CV). The medium was collected after the final incubation and IL-6 levels secreted 
after the final 8 hours assessed (Quantikine HS Human IL-6 ELISA, R&D Systems). 
 
2.4 RNA and gene expression analysis protocols 
2.4.1 RNA extraction 
Explants of approximately 0.5g from the tissue gathered on the day of surgery were 
preserved in RNAlater solution (Life Technologies, UK Cat no. AM7021) and stored at -80°C for 
subsequent extraction. RNA was extracted using Trizol (Invitrogen, UK Cat no. 15596-018) in a 
Trizol-chloroform extraction protocol, carried out as follows: 0.8 ml of Trizol was added to 64 
 
dissolve the tissue and then re-suspended in a vortex shaker for 5 seconds X 10, and left to sit 
for 5 seconds on ice in between spins. The Trizol reagent was then removed from the sample 
avoiding any pelleted debris and transferred to a new cold tube. The volume was recorded and 
fifth of the recorded volume of chloroform (Sigma, UK Cat no. 496189) was added. The sample 
was re-suspended in a vortex shaker for 15 seconds and left on ice for 5 minutes. The sample 
was then centrifuged for 15 minutes at 14,000 rpm and 4°C, and the aqueous phase collected 
and an equal volume of isopropanol added (Sigma, UK Cat. No. I9516). The samples were left 
at -20°C for 1.5 hours and then centrifuged again for 15 minutes at 14,000 rpm/ 4°C. The 
supernatant fraction containing the precipitated RNA removed very carefully and pelleted. The 
pellet was washed twice with 0.8 ml of 75% ethanol (Sigma, UK Cat no. E7023) and centrifuged 
for 5 minutes at 14,000 rpm/ 4°C. The ethanol was then carefully removed from tube and the 
pellet dried on ice for 10 minutes to remove the remaining trace amounts of ethanol. After a 
final re-suspension of the pellet by adding 45µl of RNAse-free H2O (Life Technologies, UK Cat. 
No. 4387936) the sample was assayed for concentration and purity from contaminants by 
recording 260nm/280nm and 260nm/230nm absorbance wavelength ratios (NanoDrop ND-
1000 spectrophotometer, Thermo Scientific, USA). 
2.4.2 cDNA synthesis 
For gene expression analysis, the isolated RNA from the samples in the previous section was 
used (500ng per sample), and the sample quantity adjusted for the amount of RNA sample 
taken. For reverse transcription, a TaqMan reverse transcription reagent kit was used (Applied 
Biosystems, UK Cat no. N8080234) and the proportions of reagents adjusted to the total reaction 
volume which varied per sample and the final reaction step was carried out on a Techne Genius 
FGEN05TP (Techne, UK) thermal cycler, incubated with settings as indicated by kit manual. 
Samples were kept long-term by storing in a -20°C freezer for repeat use. 
2.4.3 Real-time PCR 
Transcripts encoding for various genes from the cDNA samples created were measured by 
Real-time PCR on an Applied Biosystems ABI7900HT machine (Applied Biosystems, UK), using ABI 65 
 
SYBR Green master mix (Applied Biosystems, UK Cat no. 4368708). Primers were obtained from 
Qiagen,  (Crawley,  UK  Cat  numbers  variable  according  to  specific  gene  used,  consultable  at 
http://www.qiagen.com/products/catalog/assay-technologies/real-time-pcr-and-rt-pcr-
reagents/quantitect-primer-assays), and protocol was adjusted according to the instructions on 
the user manual. The control gene for every assay selected as a reference for the expression levels 
of the assayed gene was β-actin (Cat no. QT00094850), and total volume cDNA used was set at 
1/40th of the original cDNA total reaction volume, with a total master mix/sample/primer solution 
of 25µL in each well. PCR protocol was carried out according to primer manufacturer specifications 
in the user manual. Software analysis of the resulting cycle threshold values was carried out on 
Sequence Detection Software 2.4 (Applied Biosystems, UK), and quantified as relative expression 
compared to the control gene using the Livak method (167) as also specified in the statistical 
analysis section in this chapter.   
2.4.5 siRNA knockdown in adipose tissue 
Following  a  method  previously  described  by  Puri  et  al,  (168),  0.05  to  0.06  grams  of 
subcutaneous adipose tissue (16 explants in total, 4 for each miR-146b siRNA type) were cut 
from an explanted sample of subcutaneous fat from a bariatric surgery patient. The pieces were 
then minced into 1-2 mm fragments and placed in cuvettes containing 200μL of sterile PBS 
containing 15nmols of the desired siRNA type (AllStars Negative Control – Cat no. SI03650318, 
MiScript Negative Control - Cat no. 1027272, mi-146b siRNA mimic – Cat no. SI05362297 and 
mi-146b  inhibitor  siRNA  –  Cat  no.  SI05362287  all  obtained  from  Qiagen,  USA).  The 
electroporation experiment was then carried out in the cuvettes by subjecting the submerged 
pieces of adipose tissue to 16 shocks at 50V and 950μF on a BioRad GenePulser II electroporator 
(BioRad, USA) with shock duration of 30msec, square wave setting. The procedure involved 
shocking the tissue 8 times, then gently tapping the cuvette to mix the PBS/adipose tissue 
solution  and  the  shocking  another  8 times.  After the  final  shocks  the  tissue  solution was 
supplemented immediately with 1ml of DMEM + 10% CCS + Penicillin/Streptomycin solution, 
and taken to a tissue culture hood where it was transferred using sterile needles to a 24-well 66 
 
plate and supplemented with an extra 1.5ml of DMEM, with medium changes occurring at 2h, 
4h, 24, 48 and 65 hours after the start of the first incubation, reducing the total medium in the 
wells to 2ml instead of the previous 2.5ml after 24 hours. After 65h hours of incubation half the 
explants were incubated with CellGro + Penicillin/Streptomycin as a control, whereas half were 
incubated in CellGro + p/s with 10ng/ml of IL-1β for 8 hours total, with the medium collected 
and stored at -80°C and the adipose tissue placed in RNAlater solution, stored at the same 
temperature  at  the  end  of  the  incubation.  The  resulting  gene  expression  changes  were 
examined via RNA extraction, reverse transcription and real time PCR with methods described 
previously in this chapter.  
 
2.5 Astrocyte protocols 
2.5.1 Astrocyte cell culture 
Human primary brain stem astrocytes (ScienCell, USA Cat no. 1840) of foetal origin were 
cultured in a sterile tissue culture environment in T75 Flasks previously coated in a 50:50 distilled 
water/Poly-L-Lysine  solution  (Sigma,  UK  Cat  no.  P4707)  with  15ml  Astrocyte  Medium 
supplemented with Astrocyte Growth Supplement, Penicillin/Streptomycin solution and 5% 
Foetal Bovine Serum (all supplied by ScienCell, USA Cat no. 1801, 1852, 0503 and 0010). T75 
Flasks (BD Biosciences, UK Cat. No. 353136) were seeded with at least 1 x 106 cells after counting 
using a Neubauer haemocytometer (Hausser Scientific, USA Cat no. 3120), and incubated at 37°C 
and 5% CO2. Passaging was carried out using 5 minute incubations with 5ml 2.5% Trypsin 
solution (Invitrogen, UK Cat no. 15090-046) which were then centrifuged at 1000 rpm and re-
suspended in an equal amount of astrocyte medium for further seeding in pre-coated flasks. 
Cells were not used past passage 15 as specified by supplier manual, and passage number was 
recorded at every flask change. Medium was changed every 24-36 hours according to confluency 
of flask and rate of growth of the cells judged using an inverted light microscope (Nikon, Japan).  
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Passage 5-10 astrocytes grown in pre-coated T75 flasks at 37°C and 5% CO2 in Astrocyte 
Medium  (ScienCell,  USA)  supplemented  with  Astrocyte  Growth  Supplement, 
Penicillin/Streptomycin solution and FBS were passaged and evenly split after counting in the 
wells of a 6-well plate (Corning, USA Cat no. 3335), and grown in 1.5ml Astrocyte Medium 
supplemented with  Astrocyte Growth Supplement and penicillin/streptomycin solution but 
without the addition of Foetal Bovine serum overnight (16 hours) in separate containing the 
various molecules (Human recombinant NPY from Tocris Bioscience, UK Cat No. 1153 and 
Noradrenaline from Sigma, UK Cat no. A7257, Leptin from Peprotech, USA Cat no. 300-27). The 
cells  were  then  lysed  to  extract  RNA/protein  according  to  respective  protocols  described 
previously in this introduction. The levels of secreted IL-6 and MCP were all expressed as a 
percentage increase over the control levels of untreated baseline secretion by the astrocytes. 
All astrocyte incubations were adjusted for the volume of protein present in each well in order 
to avoid quantification errors that could arise from different growth rates in different wells. 
2.5.3 Quantification of astrocyte pSTAT3, cAMP, IL-6 and lactate levels 
Quantification of intracellular cAMP levels was carried out using cell protein samples 
extracted with RIPA buffer (Sigma, UK) (as described in the protein extraction section of this 
chapter) and tested on a cAMP complete ELISA kit (Enzo Life Sciences, USA Cat no. ADI-900-163). 
Intracellular pSTAT3 was also assayed via ELISA (Invitrogen, USA Cat no. KHO0481), as well as IL-
6 levels secreted by the astrocytes in the medium (R&D Systems, UK). Released lactate levels 
were quantified using a colorimetric assay (Sigma, UK Cat no. MAK064).  For the intracellular 
pSTAT3 and cAMP levels and the secreted IL-6 levels, sample preparation and actual assay were 
carried out as specified in the user manual, and analysed on specified wavelengths on a Dynex 
Opsys MR plate reader (Dynex Technologies, USA). The assay analysing secreted lactate levels 
in the medium was carried out according to manual and analysed on a FLUOstar Optima plate 
reader  (BMG  Labtech,  Germany)  according  to  manual-specified  wavelengths  and  reagent 
proportions. All results were adjusted to total protein content after a BCA assay quantification 
of the sample as previously described. 68 
 
2.5.4 Astrocyte Immunohistochemistry 
The protocol for the staining of astrocytes cultured in vitro was followed according to the 
numerous protocols for immunohistochemistry present in the available literature, and was 
carried out as follows:  after initial seeding of a passage 5-10 population of astrocytes grown in 
Astrocyte Medium (AM) with addition of growth solution, FBS and antibiotics (as specified 
previously in this section)    onto cover slips bathed in Poly-Lysine solution (Sigma, UK) diluted 
in  sterile  distilled  water  (1  in  7.5  dilution)  and  coated  overnight  at  37°C.  Upon  reaching 
confluence, the cells were washed cells with Phosphate Buffered Saline twice for 5 min each and 
incubated  with  4%  Paraformaldehyde  (Sigma,  UK  Cat  no.  P6148)  for  15  minutes.  The 
paraformaldehyde was then removed by washing PBS 2-3 times (10 min each time) and the cells 
were incubated in PBS + 15% Triton X-100 (Sigma, UK Cat no. X100) and 10% FBS (Invitrogen, 
USA Cat no. 16000044) for 30 minutes. After washing with PBS-T and 1% FBS for an additional 
10 minutes, primary antibodies for NPY receptor 1 or 5 were added to the bathing solution (both 
antibodies from Sigma, UK), and the slides  incubated in a oscillating shaker  for 12-16 hours at 
4°C. After primary antibody incubation (Sigma, UK) the cells were washed in PBS 3 times and 5 
minutes each, and secondary and rabbit-Cy5 antibody (Invitrogen, USA Cat no. A10523) was 
added in PBS solution and the cover slips left to incubate for 1.5 hours. Finally, the cover slips 
were washed with PBS twice and mounted on slides using Citifluor mounting medium (Citifluor, 
UK Cat no. AF1) and sealed with nail polish. After sealing, slides were conserved in the dark at 
4°C indefinitely. Photos of the stained astrocytes were taken at 40X magnification using an 
Olympus FluoView FV1000 Confocal microscope (Olympus, Japan). 
 
 
2.5.5 Cytokine array 
Quantification of cytokine levels in astrocyte protein extracts was carried out using a 
Human Cytokine Array Kit Panel-A (R&D Systems, UK Cat no.  ARY005). The tested human 
cytokines were as follows:  69 
 
C5a  IL-4  IL-32 alpha 
CD40 ligand  IL-5  CXCL10/IP-10 
G-CSF  IL-6  CXCL11/I-TAC 
GM-CSF  IL-8  CCL2/MCP-1 
CXCL1/GRO alpha  IL-10  MIF 
CCL1/I-309  IL-12 p70  CCL3/MIP-1 alpha 
ICAM-1  IL-13  CCL4/MIP-1 beta 
IFN-gamma  IL-16  CCL5/RANTES 
IL-1 alpha  IL-17  CXCL12/SDF-1 
IL-1 beta  IL-17E  Serpin E1/PAI-1 
IL-1ra  IL-23  TNF-alpha 
IL-2  IL-27  TREM-1 
 
Samples  were  concentrated  according  to  user  manual  specifications  and  protocol 
followed as specified by the kit manual. Samples were analysed using an Epson 636U scanner 
(Epson,  Japan)  and  digitally  acquired  using  IrfanView  open-source  software  (Available  at 
www.irfanview.com).  Protein  density  calculations  were  carried  out  on  ImageJ  software 
(National Institute of Health, USA) using the “Gels” function on the “Analyse” menu.  
2.5.6 Astrocyte gene silencing 
Passage 3 astrocytes cultured in T25 flasks were seeded in 6-well plates (at approximately 
50,000 cells per well) and grown to 70%  confluency in astrocyte medium with the addition of 
2% FBS, Astrocyte Growth Supplement and penicillin/streptomycin solution as described in 
previous parts of this section. After sufficient growth was achieved in the plates, the plates were 
transfected (along with a un-transfected control) with SilencerSelect (Ambion, USA) custom-
made siRNA molecules at 50µM specifically for human Leptin receptor (Cat. no. 4392420), 
GAPDH (Cat. no. 4390849) and a negative control (Cat no. 4390843). The siRNA molecules were 
dissolved in 1.5ml Gibco OPTIMEM reduced serum medium per well (Gibco, USA Cat no. 31985-
062)  and  transfected  with  the  same  medium  along  with  0.2%  Lipofectamine  RNAiMAX 
(Invitrogen, USA Cat. No. 13778-075) transfection reagent. The cells were transfected with the 
siRNA + reduced serum lipofectamine medium at 37°C and 5% CO2 for 24 hours, and after 
transfection a PBS wash in each well was carried out and the medium substituted with Astrocyte 
Medium + 2% FBS + Growth Solution + Penicillin/Streptomycin solution and incubated for an 
additional 24 hours. After another 24 hours the cells were washed with PBS once and RNA 70 
 
directly extracted by addition of 1.5ml of Trizol reagent, following the RNA extraction protocol 
described in 2.4.1. 
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2.5.7 Astrocyte intracellular calcium imaging 
  Primary brain stem astrocytes at passage 5-10 were seeded on polylysine-coated cover 
slips (coated as previously described in 2.5.5) (VWR, Germany Cat. No. 631-0666), and grown to 
confluency in astrocyte medium supplemented with 2% FBS (ScienCell, USA). After growth, the 
astrocytes  were  stained  by  adding  a  solution  of  0.5%  Fluo-4  Ca2+  sensitive  dye  (Life 
Technologies, USA Cat. No. F-14201) along with 5µL of Pluronic surfactant for 1.5ml of total 
medium (Sigma, UK Cat. No. P2443) to facilitate entry of the dye in the cell. The cells were then 
incubated at 37°C and 5% CO2 for 45 minutes before the cover slip was washed twice with Hank’s 
Balanced Salt Solution (with no added Ca2+) and transferred to a slide mount on an inverted light 
microscope  (Olympus,  Japan)  and  captured  and  analysed  using  Andor  iQ  software  (Andor 
Technology, UK). During an experiment, an initial phase of resting activity was recorded (usually 
3-5 minutes) before adding any molecule to the medium. After recording of an exposure to a 
molecule, 10 cells were selected at random in the field of view and monitored for intracellular 
Ca2+ fluctuation. The data for the initial control phase was then used to normalise activity for the 
rest of the experiment, and normalisation was carried out using OriginLab Origin Pro 9 software 
(OriginLab, USA).   
2.6 Statistical analysis 
All statistical analyses were carried out using IBM SPSS Statistics 20 for Windows (IBM, 
USA). Parametric variables were tested using a paired sample t-test and are displayed as mean 
(standard deviation), while non-parametric variables were tested using the Wilcoxon-Mann-
Whitney U test and displayed as median (interquartile range). Correlations were calculated 
using Pearson or Spearman’s correlation coefficient test. RNA expression was calculated either 
as a ratio of the control gene threshold cycle value (Ct) or using the -2-ΔΔCt method (167). All 
graphs were presented and compiled either in SPSS Statistics 20 for Windows or in OriginLab 
Origin Pro 9.0 (OriginLab, USA). 
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3.1 Clinical recruitment 
3.1.1 General patient characteristics  
The basic characteristics for the patients recruited in the course of this study according to 
the criteria described in Chapter 2 are summarised in Table 1. 
 
Category  MHO  PO + DM  p-value 
N  29  106   
Age(y)  39.0(9.3)  44.7(11)  0.09 
BMI (kg/m2)  46.0(6)  46.9(7.9)  0.10 
Systolic Blood Pressure (mmHg)  125.3(20.4)  132.9(20.3)  0.40 
Diastolic Blood Pressure (mmHg)  71.9(14.2)  76.6(12.8)  0.95 
Fasting Plasma Glucose (mmol/L)  4.7(0.7)  5.6(1.8)  0.02 
Insulin (miU/ml)  4.5(3.2-5.6)  13.7(7.1-16)  <0.001 
HOMA-IR  0.9(0.6-1.2)  2.2(1.5-4.1)  <0.001 
Total Cholesterol (mmol/L)  3.7(8.5)  3.9(1.2)  0.08 
LDL Cholesterol (mmol/L)  2.1(0.8)  2.2(1.1)  0.20 
HDL Cholesterol (mmol/L)  1.0(0.2)  0.96(0.3)  0.70 
Triglycerides (mmol/L)  1.1(0.9-1.7)  1.5(1.2-2.1)  0.01 
 
Data are shown as mean (SD) or median (interquartile range). 
Table 1: Patient characteristics 
   
Out of a total of 135 Caucasian patients (25 of whom were  male and the remainder female) 
screened 106 fit into the insulin resistant or diabetic group (with 31 diagnosed type 2 diabetics) 
29 (21.5% of total) were observed to be metabolically healthy according to the criteria used for 
our study.  Despite no significant differences in age and BMI of the patients between the healthy 
and non-healthy obese groups, there was a significant difference in fasting plasma glucose, 
insulin levels and HOMA-IR index, with all values being greater for the non-MHO. Triglycerides 
were also observed to be significantly  elevated in this group. Total cholesterol levels also 74 
 
appeared to be slightly higher in the PO/DM group as well as systolic blood pressure, albeit both 
not to a statistically significant level.  
3.1.2 Circulating adipokines 
In a representative subset of the above patients systemic adipokines were determined 
as an index of adipose tissue function in the two groups, Table 2. 
 
Category  MHO  PO/DM  p-value 
N  23  85   
Serum Leptin(ng/ml)  33.6(15.6-49.8)  37.0(23.1-57.2)  0.20 
Serum IL-6 (pg/ml)  3.0(1.0-5.4)  2.3(1.5-3.8)  0.80 
Serum MCP-1 (pg/ml)  290.0(139.0-380.0)  179.4(136.9-381.1)  0.50 
Serum NPY(pg/ml)  6.3(3.7-12.3)  11.4(5.4-18.2)  0.03 
Serum Adiponectin (μg/ml)  6.1(3.4-9.7)  3.0(1.9-5.2)  0.005 
Serum NEFA (mmol)  1.1(0-9-1.4)  1.2(1-1.5)  0.20 
 
Data are shown as mean (SD) or median (interquartile range). 
Table 2: Serum adipokines in MHO and PO patients. 
 
Systemic  NPY  concentrations  were  significantly  higher  in  the  PO/DM  group,  while 
conversely adiponectin levels were significantly higher in the MHO. Circulating NEFA and leptin 
levels were higher in the PO/DM, but did not reach significance. Inflammatory molecules such 
as IL-6 and MCP-1 were not different in the two groups. 
3.1.3 Locally secreted adipokines from adipose tissue explants 
  The levels of locally secreted adipokines from adipose organ cultures of samples taken 
at surgery from both depots and measured following 24-hour incubation in growth medium (as 
described  in  Chapter  2)  was  recorded  in  a  sub-group  of  samples  from  the  clinical  study 
population.  
 75 
 
Category  MHO  PO/DM  p-value 
N  11  28   
SC Adiponectin(ng/ml)  79(49-109)  77.6(55.3-102.7)  0.9 
OM Adiponectin(ng/ml)  60.0(44.8-91.1)  58.6(45.7-88.6)  0.8 
SC Leptin(ng/ml)  1.5(0.9-2.4)  3.0(1.6-4.2)  0.02 
OM Leptin(ng/ml)  0.2(0.1-0.8)  0.4(0.2-2.2)  0.3 
SC NPY(pg/ml)  2.9(2.5-3.6)  3.2(2.6-3.8)  0.7 
OM NPY(pg/ml)  13.0(4.0-28.8)  5.2(4.1-8.4)  0.08 
SC MCP-1(ng/ml)  3.2(1.1-9.3)  5.2(2.0-11.3)  0.2 
OM MCP-1(ng/ml)  2.0(0.3-8.9)  8.5(1.4-13.5)  0.08 
SC IL-6(ng/ml)  1.4(0.5-13.6)  1.1(0.4-3.2)  0.6 
OM IL-6(pg/ml)  2.6(1.9-6.3)  1.3(0.8-1.1)  0.6 
 
Data are shown as mean (SD) or median (interquartile range). 
Table 3: Adipokine secretion from tissue explants after 24h incubation 
 
In this cohort, shown in Table 3, overall leptin and adiponectin were released to a greater 
extent  from  the  sub-cutaneous,  as  opposed  to  the  omental  depot,  while  NPY  was  more 
abundant in the omental depot. Surprisingly there was no marked depot specific difference in 
the release of IL-6 or MCP-1 release.  
There was no difference in the local production of inflammatory adipokines, IL-6 and MCP-
1, between either depots of the PO/DM and the MHO population. Local abdominal adipose 
adiponectin secretion was also not different between the patients.  
Only leptin was secreted in greater quantities by the subcutaneous adipose tissue of the 
PO/DM population.  
 
3.1.4 IL-1β induction of IL-6 secretion 
In order to determine the viability and hormone responsiveness of human adipose tissue 
after explantation and further manipulation of inflammatory microRNAs such as miR-146b, the 76 
 
capability of adipose tissue to be release IL-6 in response to IL-1β after 65 hours of culture ex 
vivo from sample collection was investigated. The results of the experiment carried out on 
subcutaneous adipose tissue explants of 12 patients are shown in Table 4 and Figure 20. 
  
Average IL-6 (ng/ml/mg of tissue)   
Control  samples (n= 8)  140.4 
10ng/ml IL-1β (n = 12)  271.6 
p – value  <0.001 
 
Table 4: Average sub-cutaneous IL-6 secretion after stimulation with IL-1β 
The tissue had been in ex vivo organ cultures for upto 65h and then induced with IL-1β 
for 8h (n = number patients in group, control group is incubation without added IL-1β 65h 
post-explantation of tissue).  
 
 
Figure 20: Secretion of IL-6 from subcutaneous adipose tissue after induction with IL-1β.  
Black = control (untreated) tissue, white = tissue treated with both patient group explants 
were maintained ex vivo for 65h prior to induction with 10ng/ml IL-1β for 8h. Error bars 
represent S.D. 
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3.1.5 Patient characteristics following surgical weight loss 
  A  sub-group  of  patients  (10  MHO,  13  PO)  were  monitored  3-6  months  after  the 
operation during a follow-up visit (see study structure in methods chapter) in order to discern 
any  possible  changes  between  the  healthy  and  non-healthy  obese  patient  groups  in 
effectiveness of bariatric surgery on weight loss and metabolic parameters. 
In order to assess the clinical consequences of bariatric surgery on the two different patient 
groups, a blood test on a subset of study participants was carried out on a period ranging from 
surgery day (“before” in Table 5) to 3-6 months after surgery (“after” in Table 5). The clinical 
parameters are shown in Table 4. The significant changes observed were a weight loss, shown 
by reduction of BMI, and circulating NEFA levels in both groups. There was an increase in LDL-
cholesterol in the PO/DM group and serum adiponectin in both groups following surgery. HDL-
cholesterol increased significantly in the PO/DM group, and Insulin levels and HOMA-IR index 
only decreased significantly in the PO/DM group. While levels of NPY decreased in both groups 
it did not reach significance. Fasting plasma glucose did not change after weight loss in either 
group, however total cholesterol increased in both groups significantly.  
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Category  MHO 
MHO  p  against 
before  PO/DM 
PO/DM  p  against 
before 
n (after surgery)  10    13   
BMI (kg/m2) Before  46(6)    46.9(7.9)   
BMI (kg/m2) After  39.0(7.9)  <0.001  37.1(5.6)  <0.001 
FPG (mmol/L) Before  4.7(0.7)    5.6(1.8)   
FPG (mmol/L) After  4.9(0.4)  0.9  5.0(1.1)  0.2 
TC (mmol/L) Before  3.7(8.5)    3.9(1.2)   
TC (mmol/L) After  4.1(0.7)  0.01  4.8(0.9)  0.02 
LDL (mmol/L) Before  2.1(0.8)    2.2(1.1)   
LDL (mmol/L) After  2.4(0.8)  0.3  3.1(0.7)  0.04 
HDL (mmol/L) Before  1.0(0.2)    0.96(0.3)   
HDL (mmol/L) After  1.2(0.5)  0.2  1.2(0.3)  0.001 
Triglycerides (mmol/L) Before  1.1(0.9-1.7)    1.5(1.2-2.1)   
Triglycerides (mmol/L) After  0.95(0.9-1.1)  0.5  1.3(0.9-1.6)  0.2 
Insulin (miU/ml) Before  4.5(3.2-5.6)    13.7(7.1-16)   
Insulin (miU/ml) After  4.2(3.2-5.4)  0.9  7.4(4.1-9.8)  0.009 
HOMA-IR Before  0.9(0.6-1.2)    2.2(1.5-4.1)   
HOMA-IR  After  0.9(0.7-1.2)  0.7  1.6(0.9-2.1)  0.009 
Serum  Adiponectin  (μg/ml) 
Before  6.1(3.4-9.7)    3.0(1.9-5.2)   
Serum  Adiponectin  (μg/ml) 
After  14.3(8.6-22.8)  0.01  6.0(3.7-13.3)  0.005 
Serum NPY before (pg/ml)  6.3(3.7-12.3)    11.4(5.4-18.2)   
Serum NPY after (pg/ml)  3.9(1.5-9.6)  1  7.3(3.5-13.6)  0.07 
Serum NEFA before (mmol)  1.1(0-9-1.4)    1.2(1-1.5)   
Serum NEFA after (mmol)  0.5(0.4-0.6)  0.02  0.5(0.3-0.6)  0.002 
Data are shown as mean (SD) or median (interquartile range). 
Table 5: Patient characterises following weight loss 
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3.2 Histology investigation 
3.2.1 Adipocyte area 
With evidence discussed in Chapter 1 (and analysed using the method described in the 
relevant chapter of this thesis) regarding adipose tissue remodelling and dysfunction underlying 
some of the  differences in insulin sensitivity between  the MHO and PO, the possibility of 
morphological changes in the subcutaneous and omental depots of the two populations was 
examined.   
Subcutaneous  MHO  PO  P 
N (cells traced)  849  571   
Area (pixels)  3400(1954-5275)  5309(3154-7684)  <0.001 
Omental  MHO  PO  P 
N (cells traced)  582  739   
Area (pixels)  5059(2665-7790)  6186(3025-9653)  <0.001 
Data are shown as median (interquartile range). 
Table 6: Adipocyte size of SC and OM adipose tissue 
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Figure 21: Distribution of adipocyte area. Frequency histogram based on data in Table 6 
shows number of cells observed in the x-axis in a specific area range shown by the y-axis in 
pixels. Gray = MHO cells White = PO cells 81 
 
(A: SC Adipocyte area frequency histogram [blue are MHO n=849, green are PO n=571] B: 
OM [blue as MHO n=582, green as PO n=739] adipocyte area frequency histogram) 
Table 6 and Figure 21 show that both depots of the PO patients had significantly larger 
adipocytes compared to the MHO, as estimated by area. Figure 21 displays a shift in frequencies 
of the larger adipocytes in both the SC and OM depots of the PO individuals, while Table 6 that 
the overall size (area) of the adipocytes was larger in the PO compared MHO tissue. 
 
3.2.2 Adipose tissue CD68+ cells  
In  order  to  gage  inflammatory  cell  infiltration  into  the  adipose  tissue  that  putatively 
accompanies  the  adipocyte  hypertrophy  the  presence  of  “crown-like  structures”  was 
investigated (48). These structures should contain CD68+ monocyte macrophages. However, no 
significant difference in CD68+ staining between MHO and PO patients (Table 7) were apparent. 
Despite the presence of crown-like structures in some patients this seemed independent of 
metabolic status (Figure 22A). 
 
Group  MHO  PO  p value 
N (number of patients)  4  9   
SC DAB (pixels) 
1670.5 
(983.8-2558.5) 
1717.0 
(1097.0-2862.0)  0.39 
OM DAB (pixels) 
2070.5 
(999.0-3260.0) 
2075.0 
(1273.0-3172.0)  0.88 
p value  0.12  0.52    
Data are shown as median (interquartile range). 
Table 7: Histological quantification of inflammatory cell infiltration. 
CD68+ DAB staining in SC and OM adipose tissue of MHO and PO patients.  
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Figure 22: Inflammatory cell infiltration into adipose tissue. 
(A) CD68+ staining in SC (i) and OM (ii) adipose tissue. Boxplots for SC (B) and OM (C) show 
no difference in DAB staining between MHO and PO patients. Error bars represent SD 
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3.2.3 NPY receptor staining in tissue 
   Systemic NPY is elevated in the PO/DM cohort (Table 2), along with local release of the 
peptide from both adipose depots (Table 3) and adipocyte hypertrophy. In order to investigate 
the direct effects of NPY in these depots in an autocrine/paracrine fashion the expression of NPY 
receptors were investigated, with NPY receptors 1 and 5 being specifically investigated in line 
with previous studies in the RNA expression of these receptors showing them to be detectable 
as well as previous studies in the literature.  
NPY receptor expression was detectable on the adipocyte cell surface but this was not 
different between the depots or the groups (Table 8 and Figure 23). 
 
Tissue DAB stain (AU)  MHO (n=4)  PO (n=8)  p-value 
Y1 SC  6300.0 (4783.3-9823.3)  6132.5 (4193.7-7875.5)  0.44 
Y1 OM  8836.5 (4681.3-18499.5)  7801.5 (6530.3-10205.3)  0.61 
  MHO (n=4)  PO (n=8)  p-value 
Y5 SC  6551.0 (2968.5-7242.0)  4940 (3826.5-6769.5)  0.80 
Y5 OM  10207.0 (6787.0-7242.0)  8486 (6349.8-12068.3)  0.73 
Data are shown as median (interquartile range). 
Table 8: NPY receptor expression. 
Immunohistochemistry quantification in arbitrary units (AU) between MHO and PO  
subcutaneous and omental adipose tissye 
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Figure 23: NPY receptors Y1 and Y5 in MHO and PO adipose tissue. 
(A = Y1 receptor density, B = Y5 receptor density, C = example staining in adipose tissue with 
(a) Y1 receptor and (b) Y5 receptor antibody. Error bars represent SD 85 
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3.2.4 Blood vessel-associated NPY receptor quantification 
As NPY is a potent vasoactive molecule the expression of its receptors associated with the 
vasculature was further probed.  
 
Vessel DAB stain (AU)  MHO (n=12 vessels)  PO (n=30 vessels)  p-value 
Y1 SC  0.1198 (0.0989-0.1976)  0.1777 (0.1495-0.2297)  0.04 
Y1 OM  0.1242 (0.1053-0.1485)  0.1353 (0.1155-0.1800)  0.37 
p-value  0.64  0.03   
  MHO (n=6 vessels)  PO (n=21 vessels)  p-value 
Y5 SC  0.1165 (0.978-0.1245)  0.1777 (0.1274-0.2426)  0.006 
Y5 OM  0.1342 (0.1061-0.1923)  0.1973 (0.1576-0.2399)  0.02 
p-value  0.35  0.66   
Data are shown as median (interquartile range). 
Table 9: NPY blood vessel staining quantification 
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Figure 24: NPY receptor Y1 and Y5 staining associated with vessels in adipose tissue in the 
various patient groups from data described in table 9. (A = Y1 receptor, B = Y5 receptor). 
Error bars represent SD. 
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Overall much of the receptor expression was indeed associated with the vasculature. In the 
MHO both Y1 and Y5 were expressed equally in both depots. However, in the PO the sub-
cutaneous depot had higher levels of Y1 compared to omental, but Y5 was comparable in the 
depots. Further, compared to the MHO, Y1 was higher in the sub-cutaneous of the PO, while Y5 
was higher in both depots of these patients (Figure 24 and Table 9). 
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3.3 Adipose tissue transcriptional studies 
The data in the preceding section showed hypertrophy of adipocytes in both the depots of 
the PO compared to the MHO. Hypertrophy may be indicative of inhibition in adipogenesis. 
Therefore the expression of key regulators of adipogenesis was examined in the whole tissue of 
these patients via total RNA extraction. 
3.3.1 Adipogenesis: adipocyte PPARγ expression 
The expression of PPARγ2, considered to be the adipogenic “master switch” (169) was 
determined and the relative expression compared to the MHO group (Figure 25). 
 
Figure 25: PPARγ2 expression in (A) subcutaneous and (B) omental adipose tissue. Error bars 
represent SD. Values of relative expression shown against control value of 1 for MHO group 
used as reference for other PO and DM groups. 90 
 
The level of expression in the MHO patients was taken as 1 and expression in the tissue from 
the other groups shown relative to this. 
The results did not show any significant differences between the groups or the depots. The 
SC  adipose  tissue  showed  a  trend  towards  greater  (0.5-fold)  relative expression  of PPARγ 
expression in the PO compared to the MHO, with the type 2 diabetes group (DM) showing a 
comparable level. In the omental the expression was lowest in the DM (Figure 25). However, 
none of these changes were statistically significant. 
3.3.2 Metabolism: adipocyte SCD1 expression 
To probe for any change in regulators of cellular metabolism the expression of an important 
lipid  homeostasis  enzyme,  Stearoyl-CoA  desaturase  -1  (SCD1),  which  is  activated  by  the 
transcription factor SREBP-1c and is responsible for the conversion of saturated fatty acids to 
monounsaturated fatty acids (MUFA), was investigated. Expression of SCD1 may also reflect 
differences in local inflammation  given the close link between MUFA levels and adipose tissue 
inflammation (170).  91 
 
 
Figure 26: SCD1 expression in (A) subcutaneous and (B) omental adipose tissue. Error bars 
represent SD. Values of relative expression shown against control value of 1 for MHO group 
used as reference for other PO and DM groups. 
 
The level of expression in the MHO patients was taken as 1 and expression in the tissue from 
the other groups shown relative to this. 
There was a trend towards greater expression of adipose tissue SCD1 in both depots of the 
PO compared to the MHO group, with the omental depot showing the greatest difference. The 
DM group showed lower expression in the subcutaneous depot but greater expression in the 
omental.  However, none of these changes were statistically significant (Figure 26). 92 
 
3.3.3 Adipocyte NPY receptor expression 
  The mRNA expression of NPY receptors was investigated. Y1 and Y5 were the most 
abundant species.  
   
 
Figure 27: NPY receptor 1 (A, C) and 5 (B, D) RNA expression in subcutaneous and omental 
adipose tissue. Error bars represent SD. Values of relative expression shown against control 
value of 1 for MHO group used as reference for other PO and DM groups. 
   
The  differences  in  expression  between  the  groups  (Figure  27)  was  not  statistically 
significant, although the trend showed a decrease in Y1 expression with worsening metabolic 
status compared to the MHO group in both depots. Conversely, Y5 appeared to increase in both 
PO and DM groups compared to the MHO control, showing a trend towards greater expression 
with worsening metabolic status. 
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3.3.4 Adipose tissue siRNA knockdown 
As it was shown that the tissue remains responsive to cytokine stimulation for up to 65 
hours, a pilot study was carried out to knock-down a specific microRNA, miR-146b, which may 
be responsible for the inflammatory response to IL-1β in cells (171) and thought to be diversely 
modulated  in  inflamed  (and  therefore  insulin  resistant)  adipocytes  (172).  Using  the 
subcutaneous  adipose  tissue  from  a  single  patient microRNA  was  knocked  down  and  IL-6 
secretion measured with and without IL-1β stimulation.  
 
 
Figure 28: miR-146b expression knockdown in adipose tissue after electroporation and 
65h incubation. 
 
The miR-146b mimic caused an increase in the gene expression compared to the two negative 
controls, while the siRNA  dramatically decreased the levels of detectable miR-146b in the 
subcutaneous adipose tissue (Figure 28). 94 
 
 
 
Figure 29: Subcutaneous adipose tissue IL-6 secretion following tissue electroporation 
and IL-1β stimulation after 65 hours 
   
However, despite the differences in miR-146b expression in the different samples the effect 
on IL-1 β-induced IL-6 secretion by the tissue was negligible (Figure 29).  Thus miR-146b did not 
appear to modulate IL-1 β stimulation of IL-6. 
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3.4 Brain stem astrocyte in vitro studies 
Circulating NPY was shown to be secreted by adipose tissue and was specifically elevated in 
the PO/DM cohort in whom both dyslipidaemia and hypertension was elevated.  Thus it was 
decided to test the hypothesis that NPY could have an effect on cells of the central nervous 
system, specifically the brain stem, which mediates hypertension. This was investigated in vitro 
using a primary cell line of astrocytes of human foetal origin. Experiments were designed to 
simulate the effects of prolonged SNS activity on the chemosensory astrocytes. 
 
3.4.1 Astrocyte NPY receptor immunohistochemistry 
The expression of  NPY receptors on the surface of the brain stem astrocyte cells was 
confirmed using immunofluorescence and confocal microscopy. The presence of Y1 receptor on 
the cell surface was ascertained (Figure  30A), and to a lesser degree that of the Y5 receptor 
(Figure 30B). 96 
 
 
Figure 30: Astrocyte receptor Y1 (A) and Y5 (B) immunohistochemistry for detection of 
receptors on cell surface 
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3.4.2 Astrocyte NPY receptor transcription modulation in response to NPY 
  The modulation of expression of the NPY receptors in response to NPY was determined, 
along with those of other adipokine receptors, such as the leptin receptor, as well as the β 2 
adrenoceptor. Further studies examined the effect of both NPY and leptin exposure. 
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Figure 31: Astrocyte mRNA expression of (A) Y1, (B) Y5 and (C) Beta2 adrenergic 
receptors and (D) leptin receptor. Error bars represent SD 
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 Response to NPY treatment (A-C) and leptin receptor expression in response to leptin 
treatment (D) were examined. 
 
The Y1 and Y5 receptors were expressed at the mRNA level as confirmed by Figure 31A and 
Figure 31B, as well as the presence of adrenergic receptor β2, although expression did not seem 
to change after overnight NPY exposure. The astrocytes expressed human leptin receptor and 
modulation of expression occurred after exposure to 50ng/ml leptin overnight at a statistically 
significant level with an overall decrease in total expression to about half that of the control. 
3.4.3 Astrocyte NPY/adrenergic receptor transcription in simulated SNS activity 
Due to the lack of modulation with NPY alone in the preliminary results, the next part of the 
investigation into astrocyte susceptibility to SNS activity was to determine the presence and the 
reactivity of receptors in the conditions of simulated SNS activity,  with the presence of  a 
neurotransmitter, noradrenaline, and NPY in combination. The expression of NPY receptor 1, 
which was more abundant in these cells, along with those of adrenoceptors β2 and α2  were 
investigated.  Treatment  conditions  included  the  SNS  neurotransmitter  noradrenaline  (at 
0.01μM and 0.1µM concentrations) and/or recombinant human NPY (at 10ng/ml or 2.3mM), to 
simulate heightened activity.   
There was a slight, but statistically significant, decrease in adrenergic receptor α2 expression 
after exposure to the lower (0.01µM) concentration of NA (Figure 32A). At higher doses of NA 
to 0.1µM (Figure 32B) Y1 receptor decreased significantly, along with the slight decrease in α2 
expression seen with the lower dose. NPY alone did not cause any significant changes in the 
expression of any receptors (Figure 32C). However in combination, lower NA concentration 
(Figure 32D) caused a statistically significant decrease in β2 expression as well as the decrease 
in α2 observed previously. Figure 32E showed the combination of molecules at the higher NA 
concentration, where there was a statistically significant increase in Y1 expression by 1.5-fold.  100 
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Figure 32: Relative mRNA expression in NPY receptor Y1 and adrenergic receptors β2 and α2 
in the presence of NPY and/or noradrenaline 
(A = 0.01µM noradrenaline, B = 0.1µM noradrenaline, C = 2.3nM NPY, D = 0.01µM 
noradrenaline + 2.3nM NPY, D = 0.1µM NA + 2.3nM NPY). Error bars represent SD 
 
3.4.4 Astrocyte inflammatory mediator secretion 
The effects of the combination of noradrenaline and NPY on the secretion of inflammatory 
mediators such as MCP-1 and IL-6 were investigated.  This was done with the rationale that 
inflammation could compromise functionality of the brain stem astrocytes and damage their 
chemo- and baroreflex regulatory capacity.  
Other than IL-1β (positive control), only NPY (2.3nM) significantly induced MCP-1 release 
from these cells (Figure 33A). However NA (0.1µM), NPY (2.3nM) and the combination of NA (at 
0.01 and 0.1 µM) with NPY (2.3nM) all caused significant IL-6 release from astrocytes (Figure 
33B). 103 
 
 
Figure 33: Astrocyte IL-6 (A) and MCP-1(B) secretion after overnight exposure to NA 
and/or NPY concentrations. Error bars represent SD 
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3.4.5 Intracellular signalling molecules and IL-6 secretion 
In order to elucidate the intracellular signalling molecules that facilitate the NA and NPY 
mediated  IL-6  release  phosphorylated  STAT3  (pY107)  and  intracellular  cAMP  levels  were 
assayed following exposure to NA and NPY at three different time points. A rapid and sharp 
increase in intracellular cAMP was apparent after 30 minutes of exposure to NA, NA+NPY and 
the positive control (Figure 34). The remaining time points did not show significant differences 
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Figure 34: cAMP responses for NA and/or NPY at (A) 30 minutes (B) 1 hour and (C) 3 hours 
after start of incubation. IL-1β used as a positive control. Error bars represent SD 106 
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pSTAT3 was elevated after 30 min exposure to NPY and NA+NPY (Figure 35A) and at 1 hour 
(Figure 35B) and after exposure to NA, NPY and the combination. This response started to 
decrease after 3 hours (Figure 35C).  
   
Figure 35: pSTAT3 responses for NA and/or NPY at (A) 30 minutes (B) 1 hour and (C) 3 hours after 
start of incubation. IL-1β used as a positive control. Error bars represent SD 108 
 
3.4.6 Intracellular secondary messengers and IL-6 secretion 
A series of experiments were carried out to increase levels of intracellular cAMP using 
various  drugs  such  as  Forskolin  (an  adenyl  cyclase  activator),  3-isobutyl-1-methylxanthine 
(IBMX,  a  nonselective  competitive  inhibitor  of  phosphodiesterases)  and  Dibutyryl-cAMP 
(dbcAMP, a cAMP analogue and also an inhibitor of phosphodiesterases) to confirm intracellular 
cAMP as the mediator of IL-6 secretion in astrocytes.  
 
Figure 36: IL-6 secretion following overnight incubations with concentrations 
intracellular cAMP-boosting drugs. Error bars represent SD 
All the agents used to boost intracellular cAMP resulted in significantly increasing IL-6 
secretion, with Forskolin eliciting the highest rise. The control cells showed a basal level of IL- 6 
secretion which was comparable to the previous overnight incubations.  
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3.4.7 IL-6 incubation and astrocyte lactate release 
Having observed the increase in IL-6 secretion caused by the heightening of intracellular 
cAMP  levels,  the  next  step  in  the  investigation  of  the  possible  effects  of  heightened 
inflammation levels (such as the increased levels of IL-6 in local tissue) on the regular function 
of astrocytes was to examine one of the most important known functions of astrocytes, that of 
releasing lactate as an energy substrate to neighbouring neuronal cells, as well as having a 
possible signalling function towards long-term synaptic plasticity. The levels of secreted lactate 
from a population of in vitro cultured brain stem astrocytes were assayed in the presence of IL-
6 at different time points. 
 
Figure 37: lactate release in astrocytes exposed to 10ng/ml IL-6 at (A) 1 hour, (B) 3 hours, 
(C) 6 hours and (D) 24 hours after initial exposure. Error bars represent SD  
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The results shown in Figure 37 show that in every time point observed, the quantity of 
released lactate (measured in picomoles and adjusted to protein content in each well measured) 
and is significantly higher from the control incubation and denotes an increased overall level of 
heightened secretion activity. 
 
3.4.8 Astrocyte cytokine array quantification 
Since the variation of IL-6 release and its effects on the regular secretion of lactate were 
verified, The levels of other intracellular cytokines produced by the astrocytes were also assayed 
with noradrenaline and NPY via the use of a cytokine panel array (Figure 38B, list of assayed 
cytokines can be consulted in the relevant methods section of this showing differences in a 
number of intracellular cytokines shown in Figure 38A, showing a clear variation in IL-1ra and IL-
8 levels, as well as fluctuations in the levels of other cytokines such as CXCL1 and Interferon-γ. 
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Figure 38: Astrocyte array densitometry (A) of secreted the cytokines (i) IL-8, (ii) IL-1ra, 
(iii) CXCL1 and (iv) Interferon-gamma from astrocyte incubation medium which appeared to 
change in concentration and sample array blot (B). Error bars represent SD   112 
 
 
3.4.9 Astrocyte gene silencing 
  Attempts  were  also  made  to  create  a  model  of  astrocyte  manipulation  of  gene 
expression  in  order  to  mimic  long-term  changes  in  gene  expression  that  occur  with  the 
prolonged  activity  of  the  SNS.  An  attempt  was  made  with  the  leptin  receptor,  already 
established to be present and its transcription sensitive to the presence of the hormone (see 
section 3.4.2 in this chapter). SiRNA-mediated gene silencing was used to modulate human 
leptin receptor expression in astrocytes. The results shown in Figure 39. 
 
Figure 39: LEPR gene silencing in cultured human brain stem astrocytes 
   
The results did not reach statistical significance, although the trend in gene expression 
showed that compared to the control samples (displayed as a reference value of 1) leptin 
receptor  gene  expression  lowered  to  zero  percent  of  control  expression,  while  GAPDH 
expression varied from 50% to 300% of control expression. Unfortunately, negative control 113 
 
samples  could  not  be  displayed  due  to  the  samples  being  compromised  during  reverse 
transcription.  
 
3.4.10 Astrocyte intracellular calcium signalling in response to NA and NPY 
The  quantity  of  intracellular  calcium  via  fluorescence  microsopy  and  time-lapse  digital 
photography was also explored due to evidence in the literature of a known ability of NPY to 
influence cytosolic Ca2+ levels  (173), cultured astrocytes following NPY and/or noradrenaline 
exposure were recorded using Fluo-4 ( a calcium-sensitive dye) to monitor cytosolic calcium. 
After initial testing for a general response to ATP, which is a known stimulator of fluctuation of 
the intracellular Ca2+ levels (132) and would confirm the viability of the astrocytes the results, 
spanning over a series of incubations showed (as illustrated in examples by Figure 40) a variety 
of responses, specifically of a cyclical nature compared to the regular background activity of the 
astrocyte (Figure 40B) which still denoted cyclical fluctuations yet of a much smaller magnitude 
compared to acute NPY exposure (Figure 40D) or noradrenaline (Figure 40C). The combination 
of the two molecules also yielded a response after an initial control period of roughly 1-2 
minutes; in the case of samples that received exposure to NA, NPY, ATP or both, the frequency 
of the waves differed in nature and intensity as shown by the graphs in Figure 40 yet were not 
quantifiable precisely in amplitude. 114 
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Figure 40: Intracellular Ca2+ oscillations in randomly selected astrocyte culture regions of 
interest astrocytes with addition (after a 1-2 minute resting state to observe baseline 
activity) of: (A) 10 uM ATP (B) No treatment (C) 10uM Noradrenaline, and (D) NPY and (E) a 
combination of both 
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Chapter 4 
 
Discussion 
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4.1 Clinical data 
4.1.1 Patient population results 
  The overall population of patients screened using the criteria described in Chapter 2 
showed a sub-set of patients (21.5% of total numbers, as shown by Table 1) which fit the criteria 
used to isolate MHO individuals. What is very interesting about the differences between the 
MHO individuals and the rest of the population is that the PO/DM group does not show a 
difference in age and BMI, yet the quantity of circulating insulin is significantly higher and is not 
sufficient  to  maintain  a  level  of  fasting  plasma  glucose  comparable  to  the  MHO  group. 
Circulating triglycerides are also higher and show an interesting and significantly higher change 
in the PO/DM population, going in line with the results shown in other studies which have 
caused serum triglycerides to be one of the possible additional biomarkers for the discrimination 
of patients from metabolically healthy and unhealthy (174,175).  The circulating adipokine data 
shown in Table 2 shows a clear difference in circulating NPY (significantly higher in the PO/DM 
group) between the two groups, which suggests that with proper and precise detection (ideally 
gas chromatography and mass spectrometry) levels of NPY could be assayed as a biomarker 
indicative of metabolic status of a patient in a clinical setting. Other studies have also looked at 
NPY as a marker of possible onset of hypertension in obesity (176) and given the relative ease 
of detection it could be feasible in a hospital to also detect metabolically unhealthy obesity. 
Higher adiponectin levels in the MHO population are in line with previous reports of higher 
adiponectin  levels  associated  with  “healthier”  metabolic  phenotypes  (177,178).  The  post-
surgical follow-up data in Table 4 appears to confirm that the levels of insulin and glucose 
(therefore also HOMA-IR) ameliorate only in the PO/DM category in a significant manner, 
despite the significant drop in BMI for both groups. NPY levels seem to drop post-surgery in both 
populations following surgery, although the trend does not reach significance in both groups, 
possibly due to low numbers which could reach significance if the population is enlarged. It is 
also worthy of note that blood pressure data was not gathered during the follow-up visits due 
to clinical time constraints, and in future studies this would be paramount to the determination 119 
 
of NPY levels decreasing to be possibly correlated with athe possible decrease of hypertensive 
symptoms in the PO patient group. 
Cholesterol levels appear to change in both groups and significantly so, but this could be a 
result  of  the  end  of  pharmacological  therapy  after  surgery  and  therefore  a  transitory 
phenomenon which could stabilise in longer periods of time. Adiponectin levels increased in 
both groups, yet the MHO population still maintained a higher level compared to the PO and 
diabetics. These results appear to point towards a greater benefit gained from bariatric surgery 
by the PO/DM population, and that MHO patients discerned from the others by biomarkers such 
as  circulating  NPY  could  be  given  alternative  means  of  more  effective  and  less  invasive 
treatment in a clinical setting. 
The issue of common identification criteria for the patients still stands, and the results point 
to  an  even  greater  need  for  common  definitions  of  MHO/PO  characterisation  due  to  our 
observation  of  such  differences  even  in  a  morbidly  obese  population,  and  the  variety  of 
definitions used to characterise the newly studied MHO patient group (as discussed in Chapter 
2).  Indeed,  the  number of  patients  approaching  22% of  total  in  the  Caucasian  population 
confirms and increasingly enforces the idea being put forward that would describe the mere 
measure of BMI as inadequate in describing the multitude of metabolic abnormalities associated 
with obesity (179). The prevalence of “healthy obesity”, as defined by the absence of diagnosed 
comorbidities in a set obese population, shows that the current BMI measure for “unhealthy” 
and “healthy” obesity could too broad for the new stratified approach to modern medical care 
which is becoming more prevalent as a greater number of factors behind human disease are 
being uncovered. Some progress is being made with the emergence of studies suggesting a 
broader view beyond BMI (75,179), but the need for a consensus is required for a more precise 
approach to the problem. 
4.1.2 Adipose tissue explants secretion 
The  adipose  tissue  from  both  patient  groups  (Table  3)  did  not  show  any  statistically 
significant differences in local adipokine secretion saved for subcutaneous leptin, which was 120 
 
significantly higher in the PO group. This could be due to the established fact in previous studies 
carried out by Skurk et al. in 2007 that larger adipocytes are known to be able to secrete more 
quantities of leptin (180), and therefore could be an indication of the fact that the subcutaneous 
adipocytes of the PO/DM group could be larger compared to the MHO group. Since other studies 
show that larger adipocytes are also more insulin resistant (181) this could be an indication of 
localised peripheral insulin resistance in the adipose tissue. What is also worthy of note is the 
lack of any statistical significance in local inflammatory marker secretion among the two groups, 
despite a trend towards a higher MCP-1 secretion in the omental adipose tissue of the PO/DM 
group, possibly showing that localised inflammation could not be the initial factor in the onset 
of insulin resistance as previously thought. NPY levels also did not change significantly at a local 
level.  
4.1.3 IL-6 secretion in response to IL-1β stimulation 
From the data showed in Figure 20, the subcutaneous adipose tissue explanted from the 
subset of patients used in the study appeared to be responsive to the well-known effects of IL-
1β on IL- 6 gene activation and secretion (182), even after 65 hours post-sample collection. This 
allowed for the use of the tissue in transcriptional regulation studies regarding inflammatory 
micro-RNAs responsible for that were carried out subsequently.  
4.1.4 Summary of clinical data 
Despite not having differences in age and BMI, 21.5% of patients observed and isolated 
under MHO criteria had significantly lower fasting plasma glucose, insulin, HOMA-IR levels as 
well as triglycerides. Circulating NPY was significantly higher in the groups observed and anti-
inflammatory adipokines such as adiponectin were higher in the MHO group, and showed lesser 
amelioration in insulin levels compared to the PO group when undergoing bariatric surgery. 
There were no differences in locally secreted inflammatory adipokines between the groups in 
both adipose tissue depots, and leptin was significantly higher in the subcutaneous depot, 
suggesting larger adipocytes in the subcutaneous depots of the adipose tissue, which could also 121 
 
mean worsened insulin sensitivity of the tissue itself. NPY was significantly higher in the PO/DM 
group, and could also suggest a higher level of SNS activity in these patients.  
 
4.2 Histology 
4.2.1 Adipocyte area 
Looking at the adipocyte areas (Table 6) in the subcutaneous, and omental depot of the 
adipose tissue belonging to the metabolically healthy obese group, a statistically significant 
difference towards smaller adipocytes among MHO patients is evident in both depots, with the 
median area of the adipocytes being considerably larger in the PO. The adipocyte population 
graphed in Figure 21 appears to shift towards greater frequencies of larger adipocytes in the PO 
patient group, and is made very clear by the population graphs of the PO adipocytes (Figure 21, 
shown in green) displaying a more prominent shape in the greater area adipocytes of the higher 
portion of the Y axis. This results indicates in a statistically significant manner that both OM and 
SC depots of the PO population have larger (and therefore more insulin resistant) adipocytes, 
and  could  explain  the  greater  secreted  quantity  of  leptin  by  the  subcutaneous  adipocyte 
explants described in the previous section.  This discrepancy in adipocyte size could  point 
towards an effective dysfunction of the adipose tissue due to the theory of impaired tissue 
expansion,  and  could  also  indicate  the  presence  of  a  slowed  adipocyte  turnover  rate  as 
described by previous studies (48). 
4.2.2 CD68+ cell infiltration in adipose tissue 
The results displayed in Table 7 and Figure 22 show no real statistical difference in the 
quantity of CD68+ stain cells in the adipose tissue of the patients, and despite the presence of 
these cells the quantity of the apparent stain was neither different not only SC and OM depots,  
nor between MHO and PO individuals. Previously characterised foci of CD68+ cell aggregation, 
referred to as “crown-like structures” (48) have been observed (Figure 22) in the tissue in line 
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a single patient population. Statistical significance possibly could be lacking due to numbers of 
samples not being high enough, but from personal observation of the tissue the cell aggregation 
areas seemed rare and not really indicative of possible patient phenotype. These results, along 
with the lack of significant difference in locally secreted inflammatory adipokines do not seem 
to point to inflammation being the primary insult to the adipose tissue at a local level as argued 
by other groups (41). This does not exclude the idea that inflammation could be present as an 
accessory  mechanism  to  the  onset  of  insulin  resistance  once  the  primary  factors  such  as 
impaired adipocyte turnover and adipocyte hypertrophy have come into play, but from the data 
it does not appear to be the primary cause of dysfunction in Caucasian morbidly obese patients. 
4.2.3 Overall NPY receptor staining in adipose tissue 
The  staining  present  in  the  adipose  tissue  did  not  shown  any  statistically  significant 
differences in NPY staining (Table 8), therefore not indicating any overall striking differences in 
staining, yet the receptor staining was detectable visually (Figure 23) and appeared to be 
abundantly expressed throughout the tissue, suggesting a susceptibility of the adipose tissue to 
the effects of NPY secretion in possibly an autocrine as well as paracrine and endocrine manner. 
The evidence showing that adipocytes are susceptible to NPY signalling in a way that affects the 
functioning  of  glucose  transporters  (160)  in  an  insulin-independent  manner  suggests  that 
peripherally secreted NPY could be an accessory cause to adipose tissue dysfunction in patients 
that have a higher secretion level of the peptide. What also appeared interesting from the 
images analysed was that NPY receptor staining was concentrated around vessels especially, 
which led to a more precise investigation of the staining around the microvessels of the tissue 
depots which will be described in the next section. 
4.2.4 NPY receptor staining in adipose tissue vessels  
What became apparent after a closer and more sectorial observation of the staining (Table 
9) was that the levels of NPY receptor associated with any vessels present in the adipose tissue 
in both groups had a greater intensity in the PO group in both depots for Y5 receptor and in only 
the subcutaneous for Y1 (Figure 24A and Figure24B). This could point to a role of NPY receptors 123 
 
Y1 and Y5 in the adipose tissue which is more confined to vascular reactivity and vascular 
responses to sympathetic nervous system stimulation.  
The idea that NPY-potentiated vasoconstriction could be happening is supported by animal 
studies carried out which show potentiation of vasoconstrictive effects of neurotransmitters 
such as noradrenaline happening in both arteries and veins of animal models (149,150,183) and 
the difference in the localised vessel staining between the two populations (with greater levels 
of staining in the PO subcutaneous tissue) could also point to a greater sensitivity to circulating 
NPY levels, greater vasoconstriction in the tissue at a local level and the possibility of the tissue 
also being more prone to hypoxic conditions, which are known to cause insulin resistance in 
adipocytes (184).   
Overall this human data also points to an important aspect of adipose tissue biology, which 
is the important role that is played by perivascular fat and its signalling in influencing vascular 
and microvascular reactivity. The role of perivascular fat not only in major blood vessel function 
(185) but also in local adipose tissue vascular function has been extensively discussed in recent 
years (186).,It is a known fact that lack of vascular reactivity deriving from the presence of 
heightened local inflammation of the adipose tissue microvessels not only leads to lack of 
vasodilation and hypoxic conditions as previously discussed, and increased NPY signalling in PO 
individuals exacerbate NA-mediated vasoconstriction as shown in previous research could be a 
part of the alterations that lead to the problems leading to insulin resistance in humans. 
4.2.5 Summary of histological investigation data 
Histology investigation following the preliminary clinical data showed that not only did the 
tissue show differences in adipocyte size but that it also showed no statistically significant 
difference in the presence of CD68+ positive cells, which were present although not markedly 
more in the tissue of the PO group. The staining for NPY showed that receptors Y1 and Y5 were 
expressed and therefore showing a level of sensitivity in both depots, yet after an initial screen 
showing  no  difference  in  overall  expression,  the  levels  of  staining  associated  with  the 124 
 
microvessels of the adipose tissue showed a significantly higher level of staining in Y5 for both 
depot and in the subcutaneous for Y1 in PO patients compared to the MHO group.  
This  would  suggest  a  higher  susceptibility  at  the  vascular  level  to  the  effects  of  NPY 
signalling, that could also suggest additional hypoxic conditions caused by decreased blood flow 
at the local level that could increase insulin resistance in the adipose tissue of the PO patients 
in response to SNS activity. This type of hypothesis could also be confirmed by looking at the co-
localisation  of  sympathetic  nerve  fibres  with  the  NPY  receptor  staining,  to  also  confirm 
differences in sympathetic innervation at the adipose tissue level. 
An aspect that could also be interesting to explore in future studies is the presence of 
differences in UCP1 expression between depots and patient groups, in order to assess whether 
NPY signalling is having a “browning effect” on the tissue at the local level, or on the contrary is 
inhibiting the regular development and function of brown adipose tissue in humans, since this 
effect has been explored systemically in animal models with studies such as Chao et al. (187) 
showing that RNAi-mediated NPY expression knockdown in the dorsomedial hypothalamus led 
to  an  increase  in  brown  adipose  tissue  depots,  decreased  white  adipose  tissue  depots. 
Observing the presence and difference in prevalence of UCP1 expression in human adipose 
tissue between the two patient groups could be an interesting facet to the expression of NPY 
receptors in the adipose tissue, and could possibly point to more intricate differences not visible 
merely by npy receptor differences alone. 
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4.3 Tissue RNA transcriptional studies 
4.3.1 PPARγ expression in adipose tissue 
The initial analysis of the morphological characteristics of MHO and PO adipose tissue 
allowed the hypothesis that the presence of enlarged adipocytes in the PO group could be due 
to the difference in the quantity of adipogenic signals the tissue is subjected to, and therefore a 
difference from the smaller, more numerous adipocytes that could be populating the MHO 
tissue to the fewer, larger and more insulin resistant adipocytes that could be present in the PO 
tissue. By looking at the transcription level of a master adipogenic switch like PPARγ (Figure 25) 
the results showed a trend towards more adipogenic “signal” in the PO adipose tissue by about 
50% of MHO expression levels, and about the same with the diabetics in the subcutaneous 
depot. The trend appeared to be different in the omental tissue, with lesser PPARγ expressed in 
the PO group and the DM group, almost to show less adipogenesis occurring with worsening 
metabolic status as to show impaired remodelling of the tissue. The limitations to these results 
on the other hand are that statistical significance was not reached in the differences in gene 
expression, and that a higher transcription level and more active adipogenic signalling at the 
RNA level could not exactly translate to the effect being seen at the cellular level, with many 
other regulators of signalling coming into play in the differentiation of pre-adipocytes into 
adipocytes.  
The level of PPARγ transcription effectively does seem to reach a higher level in obese 
individuals in both subcutaneous and omental adipose tissue, compared to lean ones as shown 
by other studies (188,189), although the difference in expression appears to be minimal as well. 
Increasing  numbers  of  the  screened  patients  for  all  populations  would  probably  show  a 
significant trend in the total data, and investigations at the protein level for downstream-
activated or upstream signalling proteins of PPARγ could give a clearer picture of what is 
happening in the tissue of the PO and DM groups with respect to adipogenesis.  126 
 
Also, medication taken by the DM group might tamper with PPARγ signalling, given the 
direct effect of medication such as the thiazolidinedione group of drugs which act directly on 
PPARγ levels. 
4.3.2 SCD1 expression 
The  idea of observing  expression  levels of  the  enzyme  Stearoyl-CoA-desaturase  1  was 
devised due to its importance in converting various saturated fatty acids in mono-unsaturated 
fatty acids (MUFA) and for the link between local MUFA levels and inflammation of the adipose 
tissue, since they are hypothesized to be inflammatory activators of Toll-like receptor 4 (59,66), 
and could play an important part in the different lipid homeostasis and lipotoxicity that could 
arise from its activity raising inflammation levels locally and exacerbating insulin resistance. The 
results in Figure 26 show that despite there being a lack of statistical significance between the 
groups (possibly due to low numbers), the expression of SCD1 mRNA showed a trend towards 
being considerably higher in the PO adipose tissue compared to the MHO. The diabetic group 
appeared to show lower SCD1 expression in subcutaneous adipose tissue. However, despite the 
higher level of expression in the PO individuals, various studies have shown that a discrepancy 
between SCD1 expression levels and SCD1 protein levels in the adipose tissue exist (170) when 
observed in the morbidly obese, and therefore that looking at mRNA levels in the tissue might 
not be the most precise way to determine SCD1 activity. Ideally, further studies in this type of 
enzyme should be carried out with precise quantification of protein levels via western blotting, 
or by direct quantification of secreted PUFA levels by the adipose tissue itself using techniques 
like gas chromatography lined with mass spectrometry or a specific colorimetric assay. The 
results from the DM group may also be influenced by the medication some of the patients in 
the group might be taking as well, which could tamper with results at the local level.  
4.3.3 NPY receptor expression 
The presence of NPY receptors in adipose tissue has been established in various studies 
(155), as well as the fact that they are direct promoters of adipogenesis and pre-adipocyte 
differentiation in vitro (157), and also inhibitors of adipose tissue lipolysis (159). Figure 27 127 
 
summarised the experiments designed to detect the presence of NPY receptors 1 and 5, which 
were found to be the most abundantly expressed receptors in the adipose tissue in previous 
real-time PCR experiments and studies by Lafontan et al. (158), with the results not reaching 
statistical  significance  in  their  changes  yet  showing  an  interesting  trend  towards  lesser 
quantities  of  receptors  expressed  with  worsening  of  metabolic  status,  and  increased  Y5 
expression with the worsening of metabolic status. Y1 receptor expression is known to be lower 
in  lean  individuals  compared  to  obese  individuals  (190),  yet  the  differences  in  expression 
between metabolic profile of morbidly obese individuals has never been explored, and our 
results despite a lack of statistical significance would show a trend towards lower expression of 
the receptor in the adipose tissue with a worsened metabolic phenotype. This could be due to 
the down-regulation of the receptor at the gene level after its stimulation in a negative-feedback 
loop caused by higher circulating levels stimulating the receptor more frequently than in MHO 
individuals. The stimulation of Y1 receptor could be causing a decrease in insulin sensitivity by 
the blocking of translocation of GLUT transporters reported in studies such as Gericke et al. 2012 
(160), as well as levels of basal lipolytic potential of the adipocytes being affected, causing them 
to retain lipids and remain larger than other adipocytes less subject to NPY signalling.  
Y5 expression on the other hand appeared to increase in the adipose tissue of the PO and 
DM individuals in both depots, which is also interesting due to the recent hypotheses of Y5 
receptors  being  involved  in  the  remodelling  and  angiogenic  processes  of  the  tissue 
(155,156,191). The increased transcription of the receptor could point to a vascular response of 
the tissue towards angiogenesis, which could support the impaired remodelling hypothesis 
behind adipose tissue dysfunction. Since the histology results showed a level of expression on 
the surface of the adipocytes as well as the vessels in the adipose tissue, the confirmation of the 
presence of NPY receptors 1 and 5 in the adipose tissue points to an interesting role for NPY and 
SNS activity on the regular functioning of the adipose tissue and the onset of its degeneration 
in PO and DM individuals.  
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4.3.4 Adipose tissue siRNA electroporation and knockdown of miR-146b 
The data displayed by Figure 28 clearly shows an increase of miR-146b expression in the 
mimic siRNA electroporated in the subcutaneous adipose tissue compared to the levels of miR-
146b expressed in the negative controls. The inhibitor siRNAs electroporated, as expected, 
appear to have decreased the level of expression also compared to the negative controls, 
demonstrating that the electroporation experiment has worked as expected. On the other hand, 
the decreased intracellular levels of miR-146b did not appear to influence the inflammatory 
response that IL-1β elicited by causing increased secretion of IL-6. 
This could possibly indicate that the microRNA does not appear to have a direct role in IL-6 
secretion regulation in adipose tissue. The limitations to this experiment were that it was carried 
out on a limited number of samples, and that the levels of IL-1β used to elicit an inflammatory 
response  were  relatively  high.  Nevertheless,  it  demonstrated  that  microRNA  regulation  in 
human subcutaneous adipose tissue using adipose tissue in a method similar to the one carried 
out by Puri et al. (168) was possible.  
4.3.5 Summary of transcription data  
  Adipose tissue, while being susceptible to the modulation of gene expression in tissue 
as shown by the electroporation experiment, shows lack of any statistically significant changes 
in gene expression between the depots of the adipose tissue in all three groups. The trends 
presented by the transcription data showed PPARγ transcription appearing to be higher in the 
PO group for subcutaneous adipose tissue and equal to MHO patients for the DM group, while 
the relative expression appeared to decrease with worsening metabolic status in the omental. 
The  expression  of  SCD1  appeared  higher  in  the  PO  group  but  lower  in  the  diabetics  for 
subcutaneous tissue and higher in PO and DM groups for omental tissue. With respect to NPY 
receptors, the most abundantly expressed receptors (Y1 and Y5) in the adipocytes showed a 
trend in lower expression in PO and DM groups for both depots, yet a higher expression in PO 
and DM groups and in both depots with Y5 receptor.  While PPARγ and SCD1 expression levels 
could  not  reflect  protein  levels  and  therefore  not  be  entirely  indicative  of  functionality 129 
 
differences, the presence of NPY receptors Y1 and Y5 as confirmed by the histology data suggest 
that the adipocytes are susceptible to their activation, and could have effects on angiogenesis 
and tissue remodelling via Y5 receptor and glucose homeostasis and lipolysis control via Y1 
receptor function.  
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4.4 Astrocyte data 
4.4.1 NPY receptor immunohistochemistry data 
Figure 30A clearly shows a very strong expression of NPY receptor Y1 and a lesser quantity 
of Y5 receptor (Figure 30B), given that the digital acquisition gain has to be adjusted much more 
strongly in order to visualise the Y5 antibody staining. What was interesting about this difference 
in the quantity of receptors present was that this also reflected the RNA expression of Y1 and 
Y5 in the astrocytes which will be discussed in the next section. There was no non-specific 
binding  by  the  secondary  and  primary  antibodies  since  the  negative  controls  used  were 
completely  dark  and  showed  no  staining.  Given  the  presence  of  the  receptors  in  the 
immunohistochemistry  imaging  and  previous  studies  demonstrating  the  responsiveness  of 
astrocytes to NPY (192) as well as proof of expression,  these results also show their presence in 
this primary cell line, allowing further experiments regarding the effect of the peptide.  
4.4.2 Responsiveness of the receptors to NPY at the mRNA level 
  Since the quality of the primary cells as a working model for NPY responsiveness was 
assessed after the receptors were found on the cell surface, the results of  real-time PCR analysis 
of NPY receptor transcription that was subsequently carried out are shown in Figure 31. The 
receptors  interestingly  mimicked  the  results  of  the  immunohistochemistry  data,  with  Y1 
receptor being the most abundantly expressed and Y5 being present at a lower level and being 
harder to detect even in its transcription. Leptin receptor mRNA expression, which was known 
to be expressed in rat astrocytes in other studies (193),  was also observed in order to ascertain 
that the astrocytes were sensitive to the effects of other hormones and were as close as possible 
to their chemoreceptor role in the human brain stem that they would normally present, and the 
expression of adrenergic receptor β2 was investigated due to its sensitivity to catecholamines 
modelling SNS activity. The results for Y1 and Y5 receptor did not reach statistical significance in 
the changes exerted by the presence of NPY, yet the trend showed a slight increase in expression 
for  both  Y1 and  Y5  receptors  (Figure 31  A  and  B)  after  exposure  to  NPY  in  an  overnight 
incubation, and could be attributed to the cell responding to the presence of NPY signalling by 131 
 
slightly  up-regulating  its  receptors.  β2  receptor  did  not  seem  to  change  expression  level 
significantly,  although  after  NPY  exposure  expression  appeared  to  decrease  slightly.  The 
decrease in expression is an interesting effect, and was decided to be explored later in further 
incubations. Exposure of the astrocytes to Leptin decreased expression of its own receptor 
significantly,  possibly  suggesting  responsiveness  and  down-regulation  of  the  receptor  in 
behaviour different to that of an NPY signalling response. This desensitization effect has already 
been observed in hypothalamic astrocytes (194) following prolonged leptin exposure with the 
different length of the time that the peptides are present in the medium, since leptin could have 
a longer half-life ensuring that signalling continues for a longer response which could regulate a 
negative feedback loop and desensitising the astrocytes at the mRNA level as well as with 
intracellular signalling.  These results show that NPY receptor can be readily detected at the 
mRNA level in the astrocytes, and that sensitivity and ligand response at the transcription level 
could be different due to different signalling pathways involved in the response, and with the 
presence of leptin mRNA transcription as well as adrenergic receptor transcription the primary 
cells show to be an interesting model for brain stem function in relation to SNS activity.  
4.4.3 Astrocyte receptor mRNA in response to SNS activity (Noradrenaline/NPY) data 
The next step in the determination of receptor transcription in the astrocytes was to mimic 
the characteristics of chronic level of SNS activity on the cell population and to see how receptor 
transcription  was  affected.  Figure  32  shows  the  various  incubations  with  NPY  and/or 
noradrenaline, and the effects on adrenergic receptors α2 (later found to also be expressed in 
the astrocytes) and β2, as well as NPY receptor Y1, the most abundantly expressed receptor in 
the astrocyte according to the mRNA expression data.  Figure 32A shows the differences in gene 
expression resulting from incubation with noradrenaline (at 0.01µM), with the only significant 
difference being a decrease in α2 expression in line with other animal studies in cardiac tissue 
showing a decrease in receptor expression following stimulation with noradrenaline (195). β2 
levels did not seem to change significantly, possibly suggesting that the astrocytes might be 
more sensitive to α2 stimulation rather than β2. The same decrease in α2 expression can be 132 
 
observed at a higher concentration of noradrenaline (0.1µM, Figure 32B), yet there is also a 
significant decrease in Y1 receptor expression.  The reason for the decrease of Y1 expression 
may be due to the signalling pathway could be due to the role of NPY as a co-transmitter of 
noradrenaline (155), where maybe an excessive stimulation of noradrenaline as mimicked by a 
higher concentration could mean a negative feedback in its co-transmitter receptors as well, in 
a concerted manner of self-regulation from excessive stimulation. Figure 32C shows mRNA 
transcription changes from a dose of NPY (2.3nM or 10ng/ml), showing no significant differences 
between the groups. The fact that NPY alone does not affect receptor transcription at all could 
mean that its effects are solely in concert with noradrenaline signalling. Interesting effects were 
seen in the combinations of noradrenaline with NPY (Figures 32D and E), where the lower 
concentration of noradrenaline (Figure 32D) caused the expected decrease in α2 expression, yet 
the decrease occurred also with β2 receptors as well. The fact that β2 receptors were also down-
regulated in a significant manner could mean that NPY is also causing an increased stimulation 
of the intracellular signalling of noradrenaline as described by previous studies in other tissues 
such as in rabbit smooth muscle cells (149), and therefore causing down regulation of the β2 
receptors as well.  Raising the concentration of noradrenaline though did not seem to elicit any 
significant changes in receptor expression, although Y1 expression significantly increased in an 
opposite manner to that of noradrenaline alone. A possible explanation to this opposite effect 
could be due to differences in secondary messengers inside the cell that the combined presence 
of noradrenaline and NPY causes, namely via alpha-adrenoceptors and calcium levels (196) 
observed in rat brain, with this potentiation causing possibly different gene expression profiles. 
What is clear from this RNA expression data is that despite a lack of consistently statistically 
significant changes for the combinatorial treatment of noradrenaline and NPY, the results and 
reaction to co-stimulation is very different from treatment with single molecules at the mRNA 
transcription level in this cell line, which could underlie changes in intracellular secondary 
messengers and overall cellular responses.  
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The data summarised in Figure 33, depicting the secretion of MCP-1 (B) and IL-6 (A), showed 
a very interesting difference between the secretions of the two inflammatory cytokines in 
response to noradrenaline and NPY. MCP-1 (Figure 33B) showed significant differences from the 
control population only in the IL-1β positive control and when incubated solely with NPY. Since 
the existing evidence  linking NPY signalling and MCP-1 secretion is scarce, the fact that a 
significant difference in MCP-1 secretion and NPY exposure is an interesting fact by itself.  
Astrocytes are known to secrete MCP-1 as a neuroprotective response to viral infections 
and inflammation in general (197), and there is also evidence of increased MCP-1 production by 
astrocytes with stimulation of adrenergic β1 and β2 receptors in human astrocytes and the 
activation of intracellular protein kinase A activity (198), yet the results in these experiments 
show a trend towards increased MCP-1 secretion but no statistical significance possibly due to 
low  numbers  or  simply  due  to  the  inhibitory  effects  of  α-adrenoceptors  being  stimulated 
simultaneously by noradrenaline. Nevertheless, MCP-1 secretion appears to be increased by 
NPY alone.  
IL-6  secretion  (Figure  33A)  on  the  other  hand  was  very  interesting  to  observe  since 
statistically significant differences were observed in all incubations except for the lower dose of 
NA. IL-6 levels increased not only by treating the cells with every treatment done with the use 
of noradrenaline or npy, but a statistically higher difference was also observed between the 
higher dose of noradrenaline and the same dose with the addition of NPY, almost to denote a 
synergistically higher secretory response in tandem with NPY. There is evidence proving that IL-
6 secretion is increased by NA stimulation in animal models (199), and that synergistic release 
of IL-6 with other peptides such as vasoactive intestinal peptide (VIP) is possible (200), yet NPY 
as a co-stimulator of IL-6 release has not yet been ascertained and could be mediating the 
mechanism in a similar way to previous studies demonstrating the increase of intracellular 
secondary  messengers  such  as  cyclic  AMP  which  are  very  important  in  eliciting  a  local 
inflammatory response .  
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Figure 34 and Figure 35 show the changes in intracellular messengers of two separate 
intracellular signalling pathways that were in the experiments following IL-6 release assays with 
noradrenaline and NPY, cAMP and pSTAT3  (JAK-STAT pathway), respectively. In Figure 34, the 
response elicited by NPY and noradrenaline is very clear, with 30 minutes (A), showing the most 
prominent  response  with  significant  increases  from  the  untreated  levels  of  cAMP  for 
noradrenaline, combination of NPY and NA and the positive control, yet not for NPY on its own.  
At other time points, namely 1 hour (Figure 34B) and 3 hours (Figure 34C) this significant 
difference disappears and is no longer visible, suggesting a rapid and quickly disappearing cAMP 
wave  after  stimulation.    The  30  minute  increase  in  cytosolic  cAMP  levels  proves  the 
responsiveness of the adrenoceptors to NA stimulation as expected as well as the increase in 
the positive IL-1β control within a short timeframe, yet still showing the synergistic effect of the 
presence  of  NPY  at  the  cAMP  level  with  the  NPY/NA  combination  incubation  raising  the 
intracellular cAMP levels the highest. This appears to be very interesting given studies pointing 
towards NPY having an inhibitory effect on adenyl cyclase (201,202), yet there is also evidence 
of a synergistic effect of NPY on adrenoceptor-mediated pathways (203), which could suggest 
an interaction in a common secondary messenger between adrenoceptor and NPY receptor 
secondary messengers. The increase in intracellular cAMP after stimulation with the various 
molecules would also explain the increase in IL-6 secretion, given that in other cell types IL-6 
release is mediated by the same secondary messenger (204). 
Figure 35 shows the response to NA and NPY via the phosphorylation of the JAK/STAT 
signalling pathway, with significant differences in signalling shown with NPY and NA as soon as 
30 minutes after the start of the incubation (Figure 35A), although the greatest significant 
differences were seen at one hour after start (Figure 35B), albeit the positive control lacked a 
statistically significant increase and only showed a trend. What is also interesting in these results 
though is that pSTAT3 levels still appear to be the highest in the combination of NA with NPY. 
At three hours, there is a decrease in the amount of phosphorylated STAT3 levels, with the 
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pSTAT3 decreasing below control could be due to a compensatory inhibitory effect in the cell 
after stimulation of the signalling pathway. What could be a limitation to the investigation of 
this specific secondary messenger in this cell type is that STAT3 is phosphorylated also as a 
response to IL-6 binding to its receptor (205), and therefore the secreted IL-6 in response to the 
increased intracellular cAMP level s in the cell could bind to the cell in an autocrine manner and 
elicit a JAK/STAT response by itself. Nevertheless, the quantity of cAMP found to be increased 
by NA and NPY synergistically these series of experiments give an interesting basis on which to 
show the increased effect of peripheral NPY signalling and chronic SNS activity on the regular 
function of brain stem astrocytes.  
4.4.6 cAMP levels and IL-6 release in brain stem astrocytes 
To confirm the fact that IL-6 secretion was mediated by the presence of heightened levels 
of cAMP in the astrocytes, cAMP levels were heightened artificially in the cells overnight via the 
use  of  phosphodiesterase  inhibitors  (dbcAMP  and  IBMX)  and  adenyl  cyclase  activators 
(Forskolin).  Figure 36 shows that after an overnight incubation with the drugs, acting in two 
separate ways to heighten the levels of cAMP in the cytosol, IL-6 release from the astrocytes 
received a dramatic and statistically significant increase compared to the control population. 
These results clearly show the type of effect seen in other studies regarding the release of IL-6 
mediated by cAMP, and clearly show the effect of the adrenoceptor pathway being involved in 
the  heightened inflammation level, yet still do not explain the synergistic effect that these cells 
show when treated in combination with NPY.  
4.4.7 IL-6 and lactate release data  
Since a greater quantity of paracrine and autocrine signalling by secreted IL-6 was explored 
in the previous experiments, the next step in the determination of an abnormal function of the 
astrocytes was to examine whether the cells changed behaviour in any of their regular functions 
in the presence of heightened inflammation levels and whether this could cause a long-term 
dysfunction in their role of metabolic support for the neuronal circuits they surround. Figure 37 
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time point of 1 hour up to 24 hours after the start of the incubation. This difference in lactate 
secretion from cells that have a metabolism apt to providing lactate to surrounding cells as 
proved by previous research showing a much more marked tendency to produce and secrete 
lactate more than needed by the cell in various energetic states (206,207). This increased lactate 
production compared to basal levels could be due to an immune response, of which astrocytes 
are known to be players in the brain and CNS (208), yet the increased levels of the molecule 
beyond normal ranges could be detrimental to the astrocytes themselves by causing acidosis for 
which there is evidence in vitro from previous studies (209), but what could be more interesting 
is the effect of this excessive lactate secretion on the function of neuronal circuits, since recent 
evidence generated from in vivo studies points to lactate secreted from astrocytic origins as a 
direct player in the functioning of neuronal circuits such as in the locus ceruleus (210). There is 
also evidence pointing towards an increased toxicity of lactate in aged neurons, which could also 
mean a greater vulnerability of neural networks in the CNS and brain to overall heightened levels 
of lactate for a prolonged period of time such as during chronically high levels of stress with 
concerted signalling of NPY and NA in the brain stem. This type of excess imbalance is not 
directly proven to be problematic to the functioning of neural circuitry such as the chemo 
sensitive astrocytes in the brain stem, but in vivo studies pointing towards a chronic exposure 
of NPY as problematic for baroreflex control (166), and other diseases like OSA and hypertension 
in  human  obese  patients  being  linked  with  circulating  NPY  levels  (164)  show  that  more 
investigation in this dysfunction of astrocyte is absolutely needed, given increased localized 
inflammation and abnormal control of lactate secretion as an inflammatory response to NA and 
NPY stimulation.  
 
4.4.8 Astrocyte cytokine array 
The heightening of inflammation levels caused by noradrenaline and NPY stimulation of 
astrocytes was postulated to not be confined to IL-6 secretion, as there could be many other 
cytokines up-regulated by synergistic effects of the NA and NPY. In order to test this, a cytokine 137 
 
panel array was carried out on astrocyte cell populations to possibly point to different cytokines 
which could also be secreted.  
The results of this experiment in Figure 38 show 4 cytokines that we found to change from the 
control array to the exposed arrays, namely IL-8, IL-1ra, CXCL1, and Interferon-γ. IL-8 secretion 
in astrocytes is known to be mediated by the JAK-STAT pathway (211),  therefore an increase in 
IL-6 and an autocrine response to the molecule could also cause an up-regulation of other 
inflammatory cytokines such as IL-8 like the one observed in the array.  IL-1ra up regulation as 
seen in the NA+NPY population also is indicative of an IL-6 response since it is known to be 
secreted as an anti-inflammatory cytokine in response to IL-6 stimulation (212). CXCL1, an 
inflammatory chemokine, is also known to be secreted as a result of IL-6 stimulation in other 
cell types (213) and it increase in the array can also be linked to autocrine IL-6 exposure in the 
medium. Interferon gamma, a cytokine implicated in neuronal degeneration in vitro (214) and 
up regulated in our array, is known to have converging intracellular signals with IL-6 (215), 
therefore could be secreted also as a response to IL-6 receptor autocrine activation.  
The results shown by this array show that many other cytokines are up-regulated in 
response to local IL-6 and increased inflammation levels, which could set the stage for a possible 
degeneration of function of the astrocytes themselves, and therefore their adjacent neuronal 
networks  and  is  further  proof  of  the  theory  that  localized  inflammation  levels  caused  by 
excessive  adrenergic  receptor  signaling  boosted  by  raised  NPY  levels  could  be  leading  to 
excessive dysfunction in the brain stem.  
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4.4.9 Astrocyte leptin receptor gene silencing  
The concept of using the cell line as a possible model for indicating the damage caused by 
chronically elevated SNS activity in the brain stem also meant that the in vitro model could be 
used to simulate the conditions of chronic elevation of other hormones. This could be done by 
down regulating their receptors as well as being used to isolate the receptors responsible for 
the increased inflammatory response. 
This would mean setting up a gene silencing experiment in order to develop a way to 
eliminate the expression of specific receptors: in the experiments (Figure 39) that we started to 
test whether it was possible to silence genes in these astrocytes via the use of short interfering 
(siRNA),  used  to  silence  the  leptin  receptor  which  had  its  expression  become  virtually 
undetectable  compared  to  the  control  sample,  as  opposed  to  the  varying  amount  of 
transcription of another control gene, GAPDH which had not been affected experimentally. It is 
needed to be said that the negative control in this experiment did not show any expression due 
to the samples not being viable for real-time PCR, yet the leptin samples do show a variation in 
relative expression which is quite striking, and show a promising idea that gene silencing could 
be possible when confirmed with further experimentation. Evidence of gene silencing being 
effective with in vitro cultured astrocytes has been shown in previous studies (216), and this 
type of technique could prove very valid in determining the receptors precisely responsible for 
the synergistic inflammatory response in the astrocytes.  
4.4.10 Intracellular Ca2+ levels in astrocytes  
Cytosolic Ca2+ levels, heightened in waves by the release and replenishment of intracellular 
calcium stores are very important players in the responses to many external stimuli in astrocytes 
such as with leptin signalling (194,217), intracellular communication  (140), and was one of the 
main initial findings  which led to the consolidation of the astrocyte being much more involved 
in synaptic and neuronal activity as merely that of a scaffolding for neurons as previously 
thought (132). In the series of incubations carried out with a calcium-specific dye monitoring 
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shown by Figure 40. Initial testing with ATP, a known elicitor of intracellular Ca2+ levels (Figure 
40A) showed that the cells were responsive to the molecule with easily detectable oscillatory 
waves seen by selecting 10 cells at random and recording the resulting oscillations. The control 
activity of the cell (Figure 40B) was monitored by, along with incubations with noradrenaline 
(Figure 40C), NPY (Figure 40D) and the combination of the molecules (Figure 40E). The results 
for the control incubation were as expected, with spontaneous oscillations occurring during the 
incubation as would occur with normal signalling (Figure 40B). Incubations with the addition of 
10µM NA caused a wave-like intracellular calcium response (Figure 40C) when the molecule was 
introduced in the medium, which persisted for minutes after the initial dose was given. Since 
noradrenaline is not specific to α or β adrenoceptors, yet the only documented adrenoceptors 
in astrocytes which appear to have calcium as a secondary messenger system are the α1 group, 
which are thought to be implicated in the function of long-term synaptic remodelling after 
prolonged stimulation (218,219), it appears as though these adrenoceptors are being stimulated 
by noradrenaline and are eliciting a response via intracellular Ca2+ levels, and this could be 
evidence pointing to the fact that despite their being expressed at a very low and almost 
undetectable way at the RNA level, α1 receptors are present on the membrane and eliciting a 
response  in  these  cells.  Oscillations  occurred when  the cells were exposed  to 10µg/ml of 
neuropeptide Y (Figure40D), with the difference that the oscillations appeared to have a higher 
intensity compared to the ones elicited by NA. This shows that the evidence previously gathered 
in other studies in the literature showing the ability of NPY receptors to open intracellular 
calcium stores (173,203,220) is valid in the case of these cells as well, and could be contributing 
to the activation of protein kinases like protein kinase C (221) as well as the traditional protein 
kinase A pathway activated by β-adrenoceptors. The combination of the molecules also showed 
a prolonged oscillatory response as well, yet the activation of both secondary messengers 
(cAMP, Ca2+) could be simultaneously activated in a synergistic way like described in other cell 
types. This system of activation, of which previous studies in other cell types (222) have shown 
to be cross-talking between cAMP and Ca2+ stores in the cell could be a possible explanation for 140 
 
this increased combinatory effect of NA + NPY, and therefore could be important in explaining 
the increased inflammatory response elicited by the two molecules.  
Future work with respect to these experiments would be geared not only towards the 
selective inhibition via pharmacological means of the NPY and/or adrenergic receptors that 
could be responsible for the cytoplasmic Ca2+ fluctuations in the cell line, but would also involve 
the concomitant use of mitochondrial calcium dyes such as Rhod-2 in order to see which Ca2+ 
stores are also involved in the responses.  
4.4.11 Summary of astrocyte data 
Using a brain stem astrocyte primary cell line to simulate the effect prolonged heightened 
levels of NPY and noradrenaline could have on the functioning of specific areas of the CNS, such 
as the RVLM and other centres of breathing control, it was found that α and β adrenergic 
receptors and NPY receptors were expressed on the astrocytes, that they changed expression 
levels when exposed to their ligands and that the exposure of the astrocytes to noradrenaline 
and NPY caused a higher secretion of interleukin-6, yet the two molecules simultaneously 
caused  a  synergistic  effect  which  was  reflected  in  the  cytoplasmic  levels  of  secondary 
messengers like cAMP. The levels of IL-6 that were found to be increased were also indicative 
of metabolic dysfunction in the astrocyte by showing an increased secretion of lactate by the 
astrocytes, and the secreted IL-6 was shown to cause the secretion of other inflammatory 
mediators as an autocrine response by the cells. The cells also showed oscillatory calcium waves 
when exposed to NA and NPY, implying the presence activation of α1-adrenoceptors on the 
astrocytes as well, which could underlie the synergistic effect in inflammation of NA and NPY by 
further increasing levels of intracellular calcium in a concerted action of NPY and adrenoceptors 
as well as traditional cAMP mediated responses of β-adrenoceptors.  
The detection of increased lactate levels following inflammatory IL-6 stimulation in the 
astrocytes shows that an important aspect of neuronal regulation is modified by the increased 
inflammation levels. Lactate, as also discussed in the introduction, is an important molecule 
responsible  for  not  only  along  with  glutamate  in  the  consolidation  of  long-term  synaptic 141 
 
potentiation associated with memory development as shown in animal models (223,224), but 
also in the regular activation of neighbouring neurons (210).  
This data then could point to the increased level of lactate secretion due to a heightened 
level of local inflammation, which could lead to more to a more impaired function of the 
astrocyte itself (as also observed in other astrocyte types in animal models) and referred to as 
“reactive  astrocyte”  phenotype,  or  “astrogliosis”  (225).  Initially  observed  in  neural  tissue 
scarring and characterised by the impaired function and morphological characteristics of the 
astrocyte itself, there are a great number of molecular markers determining a reactive astrocyte 
phenotype (226), yet differences in the markers that the phenotype shows can be observed 
according to how the inflammation was elicited (225).  
This astrocyte data suggests a heightened local inflammation state, and therefore more 
research  should  be  carried  out  in  the  functional  characterisation  of  this  heightened 
inflammation level by exploring common astrogliosis markers in the cell line at the RNA and 
protein level and could give promising results in the determination of proper function of the 
astrocytes in this inflamed state and elucidation of the function of peripheral NPY signalling on 
the central nervous system in obesity in a human primary cell line.  
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4.5 Conclusions, limitations and future work 
4.5.1 Intracellular boost of noradrenergic signalling by NPY via Ca2+ levels 
The data shown by the astrocytes which describes this increase in inflammatory signalling is 
with respect to previous knowledge of astrocytic function and of regulation of neural circuits of 
the  brain  stem  interesting  since  it  brings  a  good  amount  of  novel  insight  to  the  possible 
mechanisms underlying the onset of comorbidities such as OSA, hypertension and metabolic 
dysfunctions of the adipose tissue caused by the presence of increased NPY levels boosting the 
quantity of inflammatory signalling mediated by catecholamines, at both the CNS level with 
brain stem astrocytes being the main players and in adipose tissue as well. 
 
Figure 41: possible mechanisms for potentiation of IL-6 release from astrocytes caused 
by noradrenaline and NPY in unison 
(PLC = Phospholipase C, PKC = Protein Kinase C, PKA = Protein Kinase A, AC = Adenylyl 
Cyclase, DAG = Diacylglycerol, IP3 = inositol trisphosphate, black arrow = activation, red line = 
inhibition) 
From the data gathered in the astrocyte experiments and what is known in the literature 
the mechanism for this synergy, the picture that emerges is that of increased and exacerbated 
calcium responses and cAMP responses that are being elicited by both NPY and noradrenaline, 143 
 
meaning that  as  shown  by  Figure  41,  the  actual  presence of  NA  and  NPY  in  combination 
stimulates both α and β adrenoceptors, with α1 adrenoceptor appearing to be responsible for 
the calcium increase given the fluorescence data and the known literature (218), as well as the 
direct stimulation of calcium by NPY receptor Y1 as demonstrated by the fluorescence data and 
previous studies (203). What is interesting to observe though is that despite the levels of Ca2+ 
increasing, the action of Y1 receptor is known to be inhibitory of adenyl cyclase and intracellular 
cAMP levels in other cell types such as vascular smooth muscle cells or in interaction with other 
cAMP-mediated hormone responses (173,227), yet the data from the astrocytes appears to 
show that cAMP levels are still higher than those of the cells exposed to NA alone, suggesting 
that  the  pathway  is  not  as  inhibited  as  in  other  cell  types,  or  that  the  sheer  amount  of 
noradrenaline  could  be  activating  the  pathway  regardless  of  the  actual  levels  of  both 
neurotransmitters. Another possibility that could explain the occurrence of the activation of 
both neurotransmitters is the evidence of cross-talk between the two secondary messenger 
signalling pathways (222,228–230), which could show specific interaction in this cell type as well. 
This raised level of both secondary messengers, which in the case of phospholipase C activation 
as  done  by  Y1  receptor  and  α1  –adrenoceptor  activate  isoforms  of  protein  kinase  C  via 
phospholipase activation (203,231) , and in the case of cAMP levels activate protein kinase A  
both converge on the same result of signalling the secretion of interleukin-6 (232), and causing 
the downstream increase in signalling in a synergistic manner (pathways 1, 2 and 3 in figure 38). 
With this synergistic action observed in other cell types and with other hormones along with 
neuropeptide Y, and the results from the astrocyte data and the heightened presence of the 
molecule in the circulation of morbidly obese patients with states of heightened SNS activity 
shows that it is very important to study the process in detail and to elucidate whether this type 
of concomitant signalling is behind the onset of a worsening metabolic phenotype in the human 
metabolism, and the effects of neuropeptide Y’s concerted action with SNS activity on overall 
inflammation levels in other parts of the CNS. 144 
 
Recent studies for example, Park et al. (233), showing that the elimination of NPY signalling 
via knockout of the NPY gene in rats reduces adiposity despite no change in food intake could 
lead an interesting type of further hypothesis to this study: that the targeting of NPY signalling 
from the periphery to the CNS in an inhibitory manner via receptor antagonists or monoclonal 
antibodies could mean that the paracrine and endocrine effects of the signalling could be 
eliminated, with the comorbidities arising from functional impairment of the astrocytes due to 
heightened inflammation in the brain stem possibly partially reversed in humans as well. More 
work is to be done to confirm this type of hypothesis in the ways described previously in this 
section. 
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4.5.2 Limitations of the astrocyte model and future work 
The limitations of this model is that the in vitro signaling experiments in the cell line could 
not  be  ideal  in  reproducing  the  quantities  of  circulating  neuropeptide  Y  in  physiological 
conditions, yet these experiments represent a starting point for more elaborate research, with 
specific agonists and antagonists of α and β adrenoceptors which could be used to nullify or 
single out the effects of specific types of adrenoceptors, as well as the use of specific agonists 
of various NPY receptors  in order to ascertain which receptors are responsible for the observed 
effects. Also, another experiment which could be developed is the use of phorbol esters to 
activate protein kinase C and to see whether the additive effect is observed as well.  Another 
limitation to this study is the lack of western blotting experiments to the adrenergic and the 
neuropeptide Y receptors themselves, which could be done to determine the changes of the 
receptors  expressed  at  the  protein  level  given  the  lack  of  significant  differences  in  the 
experiments exploring mRNA levels, which could also be due to small numbers of the samples 
examined.  What  could  also  be  investigated  is  the  effect  of  these  chronically  heightened 
inflammation levels on the quantity of receptors for other hormones such as leptin, which is 
very well known to be expressed by these astrocytes (147), and the effects it could have on their 
ability to sense the hormone from the bloodstream in the RVLM. The gene silencing experiments 
could also prove interesting in isolating the receptors responsible for this synergy as well, and 
would also be definitely considered for future work in the field. 
As previously also mentioned in the relevant data summary sections, the future work with 
respect to astrocytes could also be to explore the inflammation markers that are associated with 
the reactive astrocyte state observed in other models of disease and whether they could be 
found in the case of chronic NPY + NA stimulation in order to describe whether this state could 
also occur at the level of the brain stem and after NPY-potentiated NA signaling. 
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4.5.3 Development of an animal model 
Given the results of the in vitro model, the next logical step in the development of an even 
more accurate model for long term stress and SNS activity on the brain stem would be the 
development  of  an  animal  model,  either  mouse  or  rat,  that  could  be  used  for  long-term 
exposure to catecholamines and NPY levels, so the effects of this type of synergistic signaling 
could be observed in brain stem tissue slices isolated from the animals or even looking at the 
way the control of breathing and blood pressure is affected.  Similar studies such as Xie et al. 
2012 have been carried out with rats and long-term exposure to NPY (166), and were an 
inspiration in the development of these experiments to begin with.  
Long-term stress has been observed by other studies like Abe et al. 2010 also point to NPY 
as having a pivotal role in the degeneration of metabolic function in the periphery, but brain 
stem astrocyte activity and its direct link to the synchronization and control of neural networks 
like the types seen in other circuits and described in the introduction of this thesis have not yet 
been linked, and the in vitro data generated by this study shows that there is room for further 
investigation in the matter in an animal model. 
An animal model could also allow for the design of an experiment involving knockout 
mutants for NPY receptor genes like the ones used in studies of Park et al. 2014 (233), and this 
the effects of nullifying the role of NPY receptors via knockdown/knockout or pharmacological 
means could prove useful in the understanding of their role in the interplay between central 
nervous system and peripheral signaling. 
Immunohistochemistry for local IL-6 levels in the brain stem after long-term circulating NPY 
exposure on brain stem tissue slices could prove further the hypothesis that local inflammation 
could be driving the dysfunction observed in other animal models such as Xie et al, and further 
reinforce the evidence gathered by the in vitro experiments. An animal model could also provide 
indication as to the functionality of the astrocytes (and neural circuits of the RVLM) with respect 
to other hormones important for metabolic control of the adipose tissue and blood pressure, 
such as Angiotensin II and Leptin, as well as giving the opportunity to look at the functionality 147 
 
(such  as  the  presence  of  insulin  resistance  as  a  result  of  heightened  circulating  NPY  and 
catecholamine levels) of the peripheral tissues of the animal at the same time in order to 
observe NPY secretion rate. 
What could be a limitation between the use of human-derived astrocyte cell lines and a rat 
model on the other hand is that given evidence that there are differences in cell functionality in 
the regulation of inflammation between human and rat astrocytes as shown by evidence in the 
literature (234), the applicability of results could be different compared to a human in vitro 
model. Nevertheless, the overall view of NPY’s peripheral and central effects that an animal 
model could offer would give extremely important results in the elucidation of the link between 
stress, peripheral tissue function and its effects on the central nervous system. 
A possible way this study could be prolonged in the use of an animal model would be to 
combine the methodology of Xie et al. (166), with the long-term administration of NPY from the 
periphery, seeing the central effects this could have on brain stem astrocyte function either in 
vivo  directly from brain stem slices or from isolated astrocytes of the rat brain stem cultured in 
vitro.  Also, the study of NPY knockout mice such as the study by Park et al. (233) and their 
reactivity according to Y1, Y5 receptor specificity, in order to isolate the receptor which is being 
targeted at the central nervous system level and its inflammatory action on the astrocytes 
therein could be studied. 
4.5.4 DPP-IV and its effects on NPY signalling 
One of the aspects that were not fully investigated in this study was the effect of Dipeptidyl 
Peptidase-IV (or DPP-IV) on NPY’s ability to target specific NPY receptors compared to others on 
the cell surface. Since receptor specificity could change the effects of NPY‘s ability to affect 
intracellular signalling, as seen with adipocytes and is an important step in NPY processing with 
other cells as well (159,235,236), the inhibition of DPP-IV by using specific drugs such as one 
belonging to the gliptin class of DPP-IV inhibitors could give insight into which NPY receptors are 
mediating the synergistic effect on the astrocyte cell line. DPP-IV expression levels and protein 
levels investigated in the adipose tissue of the patients directly via real-time PCR or western 148 
 
blotting could probe very useful in the determination of a preferential receptor being activated 
in vivoin the adipose tissue and causing a difference in lipolytic potential of the adipocytes at 
the  local  level,  which  could  also  explain  the  hypertrophy  results  shown  by  the  histology 
investigation. The results shown in this thesis, despite DPP-IV inhibition on the other hand are 
still valid since they demonstrate physiological conditions as much as possible, and therefore 
are reflecting the physiological amount of DPP-IV activity in the cells as much as possible. 
4.5.5 Precise NPY detection 
What has also emerged during the work on NPY levels in this thesis is the difference in 
detectable levels of circulating NPY between the various studies in the literature and the results 
gathered by the means of this study. Various studies show varying overall levels of circulating 
NPY (153,164,176,237) compared to the results shown by our investigation, although serum NPY 
was  relatively  different  and  therefore  indicative  of  overall  circulating  levels  regardless  of 
quantity. What should be ameliorated in the future of studying the peptide is the detection 
method, possibly changing from a sandwich ELISA used in this thesis to more elaborate methods 
such as gas chromatography and mass spectrometry, two methods that are more precise in their 
detection of NPY levels and becoming viable in a clinical setting as well as much more popular 
in the scientific community. Undoubtedly they are more expensive than ELISA detection, yet the 
development of more economical and cheaper means of clinical analysis with the continuous 
refinement of the technologies cited could prove more advantageous in the future.  
 
4.5.6 The need for a common MHO definition 
What is shown from the results shown in this thesis, which range from the population study 
at the clinical level to tissue studies at the organ level and in vitro studies at the cellular level is 
that the molecular mechanisms underlying the regulation of SNS activity, metabolic function 
and  overall  reaction  of  the  human  body  to  excessive  energy  intake  can  vary  dramatically 
according to the factors at play, and this happening in a population which was kept at the same 
age, BMI and ethnic group, so already in a condition of being a subset singled out from the 149 
 
population of a developed country. This type of diversity that this group of patients and other 
groups has observed could have a variety of effects and is a very important source of information 
for more detailed studies like this one, yet the difference in the discrimination of patients 
between studies, and the lack of central approval from a global organization like the World 
Health Organisation of a common MHO definition makes the accurate study of the phenomenon 
and the search for hypothetic biomarkers (such as the proposed Neuropeptide Y in this thesis) 
difficult.  
Studies into the incidence of MHO characteristics among obese populations are going in the 
right  direction  by  starting  to  adopt  unifying criteria  (179)  and  also  to  take  more complex 
variables than the mere measurement of body mass index into account to classify patients in 
separate metabolic groups. But a coordinated effort is needed for a more stratified and precise 
approach  to the  emerging  problem of  obesity  in  the  developed  world,  which  as  research 
progresses and refines its techniques to solve the problems  and burdens that obesity entails, is 
also revealing a much more complex and diverse multi-variant phenomenon involving not only 
the  adipose  tissue  and  its  energetics,  but  also  the  regulatory  mechanisms  which  change 
according to patient type. 
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